















Clinicum, Department of Medicine, Faculty of Medicine,  
University of Helsinki, Helsinki, Finland 
 
Medicum, Department of Anatomy, Faculty of Medicine, 
University of Helsinki, Helsinki, Finland 
 




ORTON Orthopaedic Hospital of the  











To be presented, with the permission of Faculty of Medicine 
of University of Helsinki, for public examination at 
12:00, September 23, 2016 
Haartman Institute, Lecture hall 2 






Professor Yrjö T. Konttinen 
Department of Clinical Medicine 
University of Helsinki 
Helsinki, Finland 
 
Docent Dan C.E. Nordström 
Department of Internal Medicine 
Helsinki University Hospital and 







Professor Anne Isine Bolstad,  
Department of Clinical Dentistry 
Faculty of Medicine and Dentistry 
University of Bergen, Norway 
 
Professor Eeva Moilanen 
Department of Pharmacology  
School of Medicine 






Dosent Pia Isomäki 
Department of Internal Medicine 
Centre for Rheumatic Diseases 
School of Medicine 




ISBN 978-951-51-2360-2 (paperback) 









«A delusion is something that people believe 
in despite a total lack of evidence». 
 




«Knowing the answer means nothing; 
Testing your knowledge means everything». 
 








































































Photo by Erkki Hänninen 
 6 
TABLE OF CONTENTS 
 
 
1. LIST OF ORIGINAL PUBLICATIONS…………………………………….. 8 
2. ABBREVIATIONS………………………………………………………….. 9 
3. ABSTRACT with INTRODUCTION….……………………………………. 12 
4. REVIEW OF THE LITERATURE………………………………………….. 15 
 4.1. Salivary glands…………………………………………………….. 15 
  4.1.1. Histological structure…………………………………….. 15 
  4.1.2. Saliva…………………………………………………….. 16 
 4.2. Sjögren’s Syndrome……………………………………………….. 19 
  4.2.1. Clinical features and classification criteria………………. 20 
  4.2.2. Current view on etiology and pathogenesis……………… 23 
  4.2.3. Treatment………………………………………………… 26 
 4.3. Histamine metabolism and transport………………………………. 28 
  4.3.1. Histamine producing cells and “on/off-state” conception.. 28 
  4.3.2. Histamine synthesis, release and degradation……………. 30 
 4.4. Histamine receptors………………………………………………... 33 
  4.4.1. Histamine receptor H1……………………………………. 34 
  4.4.2. Histamine receptor H2……………………………………. 35 
  4.4.3. Histamine receptor H3……………………………………. 36 
  4.4.4. Histamine receptor H4……………………………………. 38 
  4.4.5. Constitutive activity……………………………………… 40 
 4.5. Histamine and salivary secretion…………………………………... 42 
 4.6. Apoptosis and its role in Sjögren’s syndrome……………………... 43 
5. AIMS OF THE STUDY…………………………………………………….. 47 
6. MATERIALS AND METHODS……………………………………………. 48 
 6.1. Patients and samples……………………………………………….. 48 
 6.2. H4R agonists……………………………………………………….. 49 
 6.3. HSG cell culture…………………………………………………… 49 
 6.4. NS-SV-AC cell culture…………………………………………….. 49 
 6.5. Multiplex and ELISA assays………………………………………. 50 
 6.6. Used primary antibodies…………………………………………… 51 
 6.7. Immunohistochemical staining……………………………………. 52 
 6.8. Histamine transport studies………………………………………… 52 
 6.9. Immunofluorescence staining……………………………………… 53 
 6.10. H4R internalization study in NS-SV-AC cells……………………. 53 
 6.11. Apoptosis induction……………………………………………… 54 
 6.12. Phase contrast microscopy and Flow cytometry…………………. 54 
 6.13. Western Blotting…………………………………………………. 55 
 6.14. Quantitative Real-time PCR……………………………………… 55 







7. RESULTS AND DISCUSSION…………………………………………….. 58 
 7.1. Histamine receptors profile of the salivary glands………………… 58 
 7.2. Histamine transport and metabolism in the salivary glands……….. 61 
  7.2.1. Histamine metabolizing enzymes in LSG……………….. 61 
  7.2.2. Histamine transporters in LSG………………………….. 61 
  7.2.3. Histamine transportes in HSG cells……………………… 62 
  7.2.4. OCT3 in murine salivary glands…………………………. 62 
 7.3. Non-professional histamine producing cells and “on/off-state”  
        conception in Sjögren’s syndrome…………………………………. 
 
65 
 7.4. H4R in the salivary gland cell cultures……………………………... 66 
  7.4.1. H4R regulates production of IL-8 and VEGF in HSG cells 66 
  7.4.2. Internalization of H4R in NS-SV-AC cells………………. 68 
  7.4.3. NS-SV-AC cells undergo TNFα/IMD-0354-induced  
            apoptosis…………………………………………………. 
 
69 
  7.4.4. Anti-apoptotic activity of H4R in NS-SV-AC cells……… 71 
  7.4.5. Role of H4R in Sjögren’s syndrome……………………... 73 
 7.5. Regulation of H4R expression……………………………………… 75 
8. SUMMARY AND CONCLUSIONS………………………………………... 76 
9. SUMMARY AND CONCLUSIONS in RUSSIAN…………………………. 79 
10. ACKNOWLEDGEMENTS………………………………………………… 82 






1. LIST OF ORIGINAL PUBLICATIONS 
 
This thesis is based on the following publications, which in the text are referred to by 
Roman numerals (I – III) 
 
I Stegaev V, Sillat T, Porola P, Hänninen A, Falus A, Mieliauskaite D, 
Buzás E, Rotar Z, Mackiewicz Z, Stark H, Chazot PL, Konttinen YT. 
Brief report: first identification of H  histamine receptor in healthy 
salivary glands and in focal sialadenitis in Sjögren's syndrome. 
Arthritis Rheum. 2012 Aug;64(8):2663-8. 
doi: 10.1002/art.34484. 
II Stegaev V, Nies AT, Porola P, Mieliauskaite D, Sánchez-Jiménez F, 
Urdiales JL, Sillat T, Schwelberger HG, Chazot PL, Katebe M, 
Mackiewicz Z, Konttinen YT, Nordström DCE. Histamine transport and 
metabolism are deranged in salivary glands in Sjögren’s syndrome.  
Rheumatology (Oxford). 2013 Sep;52(9):1599-608. 
doi: 10.1093/rheumatology/ket188. 
 
III Stegajev V, Kouri VP, Salem A, Rozov S, Stark H, Nordström DC, 
Konttinen YT. Activation of histamine H4 receptor inhibits 
TNFα/IMD0354-induced apoptosis in human salivary NS-SV-AC cells. 






In addition, some unpublished results are presented and designed as IV. 
 




2. LIST OF ABBREVIATIONS 
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CD cluster of differentiation 
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CXCL chemokine (C-X-C motif) ligand 
DAB 3,3'-diaminobenzidine 
DAO diamino oxidase 
DAPI 4',6-diamidino-2-phenylindole 
cDNA complementary deoxyribonucleic acid 
Do, Go, Rb donkey, goat, rabbit 
ECL-cell Enterochromaffin-like cell 
ELISA enzyme-linked immunosorbent assay 
eNOS endothelial nitric oxide synthase  
ER endoplasmic reticulum 
ERK extracellular signal-regulated kinase 
FADD Fas-assosiated death domain 
FAM fluorescein amidite 
FasL Fas-ligand 
FasR Fas-receptor 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GDP guanosine diphosphate 
GM-CSF granulocyte macrophage colony-stimulating factor 
GPCR G-protein-coupled receptor 
GTP guanosine triphosphate 
H1R H1 histamine receptor 
H2R H2 histamine receptor 
H3R H3 histamine receptor 
H4R H4 histamine receptor 
HDC histidine decarboxylase 
HIV human immunodeficiency virus 
HLA human leukocyte antigen 
HNMT histamine-N-methyl transferase 
HRP horseradish peroxidase 
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hrTNFα human recombinant tumor necrosis factor alpha 
HSG cell derivative from human HeLa cells 






JNK c-Jun signalling kinase 
K-SFM keratinocyte serum-free medium 
Kd dissociation constant 
LSG labial salivary gland 
M3 receptor muscarinic receptor 3 
MAC  apoptosis-induced channel  
MAPK mitogen-activated protein kinase 
MMP matrix metalloproteinase 
moH4R murine/mouse histamine receptor 4 
MPP  1-methyl-4-phenylpyridinium 
mRNA messenger ribonucleic acid  
MβCD  methyl-β-cyclodextrin 
NF-κB nuclear factor κB  
NK-cell natural killer cell 
NO nitric oxide 
NOD mice non-obese diabetic mice 
Noxa phorbol-12-myristate-13-acetate-induced protein 1 
NSAID nonsteroidal anti-inflammatory drugs 
NS-SV-AC normal salivary simian virus-40 immortalizes acinar cells 
OCT organic cation transporter 
PBS phosphate-buffered saline 
PI propidium iodide 
PMAT plasma membrane monoamine transporter 
PPI proton pump inhibitors 
pSS primary Sjögren's syndrome 
Puma p53 upregulated modulator of apoptosis 
PVDF polyvinylidene difluoride 
qRT-PCR quantitative reversed transcriptase polymerase chain reaction 
R-MeHA R-methylhistamine 
SCC squaomous cell carcinoma 
SEM standard error of mean 
SMG submandibular gland 
SS Sjögren's syndrome 
SSA/Ro anti-Sjögren's-syndrome-related antigen A 
SSB/La anti-Sjögren's-syndrome-related antigen B 
sSS secondary Sjögren's syndrome 
TBS tris-buffered saline 
TGX tris-glycine eXtended 
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Th cell T-helper cell 
THIO thiopyrimidine 
TLR toll-like receptor 
TNFR1 TNF receptor 1 
TRADD TNF receptor-associated death domain 
TTBS Tween-20 Tris-bufferes saline 
VEGF vascular endothelial growth factor 










Introduction. Sjögren's syndrome (SS) is a chronic autoimmune disease with yet 
unknown etiology and partly unclear pathogenesis that affects exocrine glands. 
Cardinal symptoms of the disease are dry mouth and eyes. Fas-apoptosis is considered 
as a key event in breach of autoimmune tolerance in SS. Increased levels of histamine 
in serum and tissue fluids characterize many autoimmune diseases, including SS. 
However, trials have showed ineffectiveness of H1 and H2 histamine receptor 
antagonists in the treatment of autoimmune diseases. More recently, it has been 
reported that many cells throughout the human body synthesize histamine in small 
nanomolar quantities in a non-professional manner. Unlike professional histamine-
synthesizing, -storing and stimulus-mediated burst-like -releasing cells, such as mast 
cells, basophils and ECL-cells, many other cells, including dendritic- and T cells can 
synthesize histamine at 100-1000-fold lower rate and release it continuously into the 
extracellular milieu. In the beginning this discovery drew little attention until a new 
H4 receptor (H4R) was discovered in immune cells in 1994. H4R has about 10000-fold 
higher affinity to histamine than conventional H1R and H2R. This discovery shortly 
became a hot topic and started a new era for studies of immunomodulatory 
histamine/H4R-mediated effects. Today clinical trials of H4R antagonist as treatment 
for inflammatory diseases are ongoing. 
 
Aims of the thesis project. It was hypothesized that H4R is involved in SS 
pathogenesis. To test this hypothesis the following objectives were studied: (1) 
expression of H4R in salivary glands of healthy and SS individuals; (2) H4R 
internalization and functionality upon specific agonist stimulation; (3) transport of 
histamine in HSG cells and expression of histamine metabolizing enzymes in salivary 
glands of healthy and SS individuals; (4) mechanisms of anti-apoptotic activity of 
H4R; (5) mRNA levels of moH4R in orchidectomized and intact male mice. 
 
Materials and methods. Briefly, this study was performed on snap-frozen and/or 
paraffin-embedded biopsies of minor salivary glands from SS patients, which were 
routinely taken as a part of the diagnostic procedure. Samples were considered as 
“healthy” if diagnostic criteria were not fulfilled. In vitro experiments were performed 
on two cell lines: human salivary gland (HSG) line, which is phenotypically a ductal 
 13 
epithelial line, and normal salivary Simian virus 40-immortalized acinar cell (NS-SV-
AC) line. Additionally, we were gifted by snap-frozen murine salivary glands from 
BALB/c, NOD, orhydectomized and intact HDC+/HDC+ lines. Protein expression 
levels of histamine receptors, transporters and metabolizing enzymes in tissue 
samples and cell lines were tested by immunohistochemistry and immunofluorescence 
staining, mRNA were quantified by qRT-PCR technique (including TaqMan 
technology). Two specific H4R agonists ST-1006 and HST-10 were used for in vitro 
functional (HSG), internalization and apoptosis (NS-SV-AC) cell line experiments. 
Levels of IL-8 and VEGF produced by HSG cells ± ST-1006 were analyzed by xMAP 
and ELISA assays. [3H]histamine transport in HSG cells ± OCT3 inhibitor MMP was 
analyzed by liquid scintillation technique. hrTNFα/IMD0354-indiced apoptosis of 
NS-SV-AC cells ± HST-10 was analyzed with following techniques: Western blot to 
study late apoptosis marker cPARP, anti- and pro-apoptotic proteins BAX and Bcl-
XL and phosphorylation of JNK and ERK MAPKs; flow cytometry to study Annexin-
V and PI labeling of apoptotic and necrotic cells; phase-contrast microscopy to study 
morphological changes of apoptotic cells; additionally, BAX and Bcl-XL mRNA 
levels were studied by qRT-PCR. 
 
Results. H4R was found in the acinar and ductal epithelium in healthy salivary glands 
on both mRNA and protein levels. Immunohistochemical staining showed relatively 
low H4R expression in samples from SS patients as compared to those from healthy 
controls. Healthy ductal salivary epithelium is fully equipped with a histamine 
synthesizing, transporting and intracellular degrading machinery.  SS salivary glands 
were characterized by drastically diminished expression of major histamine 
transporter OCT3 at both protein and mRNA levels. In vitro experiments showed time 
dependent up-regulated production of IL-8 and VEGF by HSG cell upon high-dose 
stimulation of H4R with ST-1006 agonist. NS-SV-AC cells express H4R, which 
internalization was delayed by clathrin inhibitor methyl-β-dextrin. qRT-PCR and 
[3H]histamine transport experiments proposed OCT3 as the major histamine 
transporter in HSG cells. hrTNFα/IMD0354-induced apoptosis of NS-SV-AC cells 
was successfully inhibited by HST-10-induced activation of H4R in a dose-dependent 
manner via inhibition of JNK MAPK pathways and up-regulation of Bcl-XL anti-
apoptotic protein. mRNA levels of salivary moH4R relatively low in orhydectomized 
HDC+/HDC+ as compared to intact control. 
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Conclusions. Salivary ductal epithelial cells are equipped with a HDC/OCT3/HNMT-
machinery therefore considering them as non-professional histamine-producing cells.  
H4R-mediated locally produced low nanomolar levels of histamine maintain 
homeostasis of the salivary epithelium. H4R activation favors cell survival.  Altered 
histamine transport together with decreased expression of H4R in salivary epithelium 
can contribute to SS pathogenesis by predisposing epithelial cells to an apoptotic pre-
condition. Mast-cell-derived high concentrations of histamine in SS salivary glands 
may excessively stimulate H4R, leading to an up-regulated production of pro-
inflammatory IL-8 and VEGF, followed by a down-regulation of H4R. Diminished 
expression of H4R in salivary epithelium in SS patients may also be aggravated by 
local/systemic androgen levels. In future, local use of low molecular weight H4R 
agonists may become an alternative for costly biologicals in the treatment of 
autoimmune diseases, including Sjögrens’ syndrome. 
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4. REVIEW OF THE LITERATURE 
 
4.1. Salivary glands 
 
The salivary gland is an exocrine gland, with one or more excretory ducts, which 
open into the oral cavity. In humans three major salivary glands exist comprising 
paired parotid, submandibular, and sublingual glands. The more superficial minor 
salivary glands are located in different areas of the oral cavity in the submucosa and 
are named based on their location to e.g. lingual, labial, buccal, molar and palatine 
glands. 
 
4.1.1. Histological structure 
The secretory acinus is a terminal segment of any salivary gland. According to the 
cellular profile, acinus can be serous (protein-secreting), mucous (mucin-secreting) or 
mixed (containing both types of the cells). Some mucous acini have a cap of serous 
cells that secrete into the highly convoluted intercellular space between the mucous 
cells (Figure 1). It is assumed that such visually observed phenomena of serous 
demilunes (caps) are a result of artificial dehydration of the serous cells during 
Figure 1. Schematic diagram of the salivon – a functional unit of the salivary gland.  
(Modified from Nanci A. In Ten Cate’s Oral Histology: Development, Structure and Function 
7th edition, 2007, Elsevier Health Sciences) 
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fixative treatment. In humans, distribution of certain acini varies between the glands. 
For instance, the submandibular gland is a mixed gland consisting mainly of serous 
acini, the sublingual gland is mostly mucous, while the parotid gland is totally serous. 
The minor salivary glands are mucous. The relative frequency of these three types of 
acini is a feature by which the salivary glands can be distinguished. 
The luminal spaces of the salivary acini open up to a ductal system, which consists 
of three sequential segments: intercalated duct, striated duct and interlobular/excretory 
duct. Depending on the nature of the acinar secretion, the ductal system may exhibit 
differently developed segments. Serous glands have well-developed intercalated and 
striated ducts to modify the composition of the final saliva by absorption and 
additional secretion. In turn, mucous glands have poorly developed segments that are 
to a lesser degree responsible for saliva modification, but simply present a ramified 
outlet system for saliva. Together with the secretory acini, these consecutive ducts 
form the main functional unit of the gland – salivon. 
The salivary acini are embraced by contractile myoepithelial cells, which also 
underlay the epithelium of the proximal portion of the duct system. Myoepithelial 
cells lie between the basal plasma membrane of the epithelial cells and basal lamina 
(basement membrane). These cells actively contribute to movement of the secretory 
products towards the excretory duct and therefore to the oral cavity. Basal lamina 
consists mainly of collagen type IV and laminins combined by nidogen-1 and 
perlecan (LeBleu et al. 2007). Basal lamina participates in the differentiation and 
maturation of the acinar cells through an outside-in signalling mechanism. Certain 
chains of laminin molecules correspond to specific epithelial cells and participate in 
the communication between basal lamina and underlying epithelial cells. For 
example, laminin α1-chain is mainly connected with the acinar cells, whereas α2-




Mixed saliva in the oral cavity is a mucoserous substance produced mostly by the 
salivary glands and to a smaller extent by the gingival sulcus, tonsillar crypts, and 
general transudation from the epithelial lining of the oral cavity. Contribution of 
different salivary glands to the total daily volume of saliva is divided as follows: 65% 
from submandibular gland, 20% from parotid, 7-8% from sublingual, and about 10% 
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from numerous minor salivary glands. Interestingly, that part from the minor salivary 
glands is very important due to resting salivary flow, which protects oral mucosal 
membrane all over the oral cavity from drying between the meals. The average daily 
saliva volume varies from 1 to 1.5 L, which exceeds other digestive secretions by as 
much as 40 times measured per weight of glandular tissue (Ross et al. 1995; 
Humphrey and Williamson 2001). 
 
Regulation of secretion 
Saliva secretion and release are regulated by both sympathetic and parasympathetic 
nervous fibers of the autonomic nervous system. Excitation of the sympathetic fibers 
in the T1-T3 region transmitted forward via sympathetic trunk results in an increase 
of mucin-rich saliva from mucous cells. Dramatically increased sympathetic 
stimulation reduces salivary flow leading to dry mouth. Parasympathetic innervation 
via the VII cranial facial nerve of the sublingual and submandibular, and via the IX 
cranial glossopharyngeal nerve of the parotid gland causes enhanced serous water-rich 
saliva production upon food ingestion (Marieb and Hoehn 2005).  
 
Formation and composition of saliva 
Primary saliva is formed upon cholinergic stimulus from the postganglionic 
parasympathetic nerve fibers, leading to intracellular Ca2+ increase. In turn, Ca2+ 
activates basolateral and luminal (apical) membrane channels, which allow escape of 
K+ and Cl− out of the cell into interstitial space and lumen, respectively. This results 
in cell shrinkage and concomitant outward flow of intracellular HCO3− after Cl−. Loss 
in HCO3− activates carbonic anhydrase mediating a conversion of CO2 and H2O into 
HCO3− and H+. De novo synthesized HCO3− anions continue to flow outwards and the 
cell undergoes acidification, which in concert with the negative potential of the acinar 
lumen draws interstitial osmotically active sodium cations (Na+) into the lumen via a 
paracellular route. Once intracellular Ca2+ decreases, Na+-H+-exchanger is activated 
and H+ cations are excreted outside the cell. Na+-coupled K+-2Cl−-inward co-
transporter brings osmotically active Na+ back to the cell, which again swells and gets 
smoothed. Na+-K+ pump (Na+/K+-ATPse) re-establishes the high intracellular 
potassium concentration and Cl−-HCO3−-exchanger restores intracellular HCO3− and 
pH. Contraction of the myoepithelial cells forces saliva out of the acinar lumen into 
the intercalated duct. Later, passing striated and excretory ducts, saliva undergoes 
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ionic modification. The ductal epithelium reabsorbs Na+ and Cl−, and secrete K+ and 
HCO3− (Nauntofte 1992). Apart from 95-99% water component, composition of 
saliva includes various ions, hormones, enzymes, immunoglobulins and cytokines 
(Humphrey and Williamson 2001). Each compound has its own function. Salivary 
histamine at resting phase varies within 3–112 nM (0.3–12 ng/ml) concentration 
levels (Kejr et al. 2010).  
 
Functions of saliva 
Among the many functions of saliva, lubrication and moistening of the oral 
mucosa could be mentioned first. Most important components of saliva, which coat 
the oral cavity, are water-binding gel-like mucins that are excreted from minor 
salivary glands. These complex glycocylated protein molecules (glycoconjugates) 
have low solubility, high elasticity, high viscosity, and strong adhesiveness. By 
lubrication and moistening they facilitate mastication, speech and swallowing, and 
also provide a molecular mechanical barrier against chemical irritants and harmful 
bacteria. Mucins have been shown to participate in the regulation of intercellular 
calcium levels and to initiate bacterial colonization of the oral cavity by benign and 
probably mucoprotective commensal flora (Denny and Denny 2008). 
Saliva also provides immune defence mechanisms for the oral cavity, which 
include systemically and locally produced immunoglobulins, lysozyme and a wide 
spectrum of antimicrobial peptides (AMP). IgA was identified to be the dominant 
form of immunoglobulins immobilizing salivary bacteria. The cationic enzyme 
lysozyme causes damage to the Gram-positive bacterial cell wall, therefore being able 
to protect oral epithelium from foreign bacteria containing peptidoglycan cell wall 
(Schenkels et al. 1995). As part of a pool of antimicrobial agents, antimicrobial 
peptides have been shown to play an important role in a cell-free immune response in 
the oral cavity (Hancock and Lehrer 1998). The most prominent representatives of 
AMPs in the mouth are cathelicidin LL-37, defensins and lactoferrin. AMP LL-37 is a 
multifunctional molecule capable of killing pathogens and modulating immune 
response, as well as stimulating mast cell histamine release. In turn, defensins have 
been shown to strengthen the antimicrobial activity of cathelicidines, augmenting the 
membrane permeabilization of target cells (Niyonsaba et al. 2001; Scott et al. 2002; 
Yang et al. 2002). Oral lactoferrin acts as an iron scavenger. The studies show that 
deprivation of iron prevents formation of pathogenic bacterial biofilms (Singh 2004). 
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Oral epithelium is known to be one of the fastest regenerating tissues in the human 
body. This repair acceleration is reached in presence of epidermal growth factor 
(EGF) in the oral mucosa and saliva (Wang et al. 1990). Along with antimicrobial 
properties, histidine-rich proteins histatins, have also been proposed to be involved in 
oral tissue repair (Xu et al. 1991; Oudhoff et al. 2008). 
Salivary amylase and lipase are involved in food digestion, degrading starch and 
lipids already in the oral cavity. Bicarbonates, phosphates, urea and carbonic 
anhydrases regulate the buffering capacity of saliva and protect against acid attack. 
Cystatins and statherins are involved in bone and teeth mineralization processes 
(Johnsson et al. 1991; Humphrey and Williamson 2001; de Sousa-Pereira et al. 2013). 
 
Factors affecting saliva production 
Hypersalivation can be caused by number of reasons and conditions, including 
various neuronal disorders, Parkinson’s disease, gastro-esophageal reflux disease and 
hyperhydration. Increased saliva production can be detected also in the case of heavy 
metal poisoning, or triggered by medicines stimulating post-ganglionic 
parasympathetic nerve fibers, such as pilocarpine, bethanechol, lithium etc., as a drug 
or side effect (Smith and Burtner 1994). 
Hyposalivation, in turn, can also be as result of medication, mainly of drugs that 
directly or indirectly interfere with the actions of acethylcholine, such as 
anticholinergic drugs, antihistamines, tranquilizers, sedatives, and beta-blockers. A 
number of systemic diseases lead to xerostomia (dry mouth). Among them (primary 
or secondary) Sjögren’s syndrome (SS), which is an autoimmune disease, takes an 
essential place (Farnaud et al. 2010). 
 
 
4.2. Sjögren’s Syndrome 
Sjögren’s syndrome is a chronic autoimmune disease, an autoimmune epithelitis, 
that primarily affects exocrine glands, resulting in their functional and finally 
structural impairment. This leads mainly to symptoms of oral, ocular and cutaneous 
dryness. The syndrome was named after the Swedish ophthalmologist Henrik 
Sjögren, who summarized knowledge on keratoconjunctivitis sicca (“dry eyes”) and 
provided the basis for future definition of the syndrome (Sjögren 1933). The 
prevalence of  primary SS (pSS) is estimated to be between 0.5 and 1% (up to 5% 
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according to some studies and definitions) (Jacobsson et al. 1989; Dafni et al. 1997; 
Pillemer et al. 2001; Bowman et al. 2004; Haugen et al. 2008) within the population, 
mainly affecting middle-aged women, with a female-to-male ratio reaching 9:1, 
sometimes even 14:1 (Garcia-Carrasco et al. 2002; Mavragani and Moutsopoulos 
2010). Secondary SS (sSS) manifests in 4-31% patients with rheumatoid arthritis, in 
9-19% patients with SLE and in 14-20% patients with systemic sclerosis (Ramos-
Casals et al. 2007). 
 
4.2.1. Clinical features and classification criteria 
Typical SS patient describes dry eyes (xerophthalmia) and dry mouth (xerostomia) 
symptoms, complaining of “gritty” or “sandy” feeling in their eyes and difficulties in 
swallowing dry food. Some patients regularly moisturize their oral cavity with small 
sips of fluids, in some cases also at night. Impaired tear fluid production, resulting in 
insufficient tear film formation, is often complicated with corneal ulceration and 
infection of the conjunctiva and Mebomian glands of the eyelids. Inadequate salivary 
flow may contribute to dental caries and oral candidiasis due to loss of the protective 
and antimicrobial properties of saliva. Among exocrine symptoms parotid swelling 
and other xeroses, such as dryness of skin and mucosa in the nose, throat or vagina, 
are frequent due to failure of the function of exocrine glands (Tincani et al. 2013). 
Cutaneous involvement can be found in up to 50% of SS patients. Most 
prominently skin xerosis affects dorsal and lateral surfaces of the extremities 
(Bernacchi et al. 2005). Other skin-related symptoms in SS patients are Raynaud’s 
phenomenon with prevalence of about 30% (Tektonidou et al. 1999), cutaneous 
vasculitis with a prevalence of about 10%, appearing as purpura, urticarial lesions, 
papules, small ulcers (Ramos-Casals et al. 2004) and annular erythemas (Kuhn et al. 
2000). 
The respiratory system also suffers in SS patients. Due to xerotrachea and 
laryngitis sicca patients may complain of persistent hoarseness and a chronic, non-
productive cough. In about 20% of SS cases recurrent bronchial and pulmonary 
infections and otitis media can take place (Mialon et al. 1997). Increased risk of 
developing pulmonary extranodal marginal zone B-cell MALT lymphoma with a 
prevalence of 1-2% have been reported (Cain et al. 1998). 
Non-exocrine manifestations of SS comprise a heterogeneous group of symptoms 
and disorders also providing evidence of systemic nature of the disease and may be 
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based on lymphocyte recirculation, immune complexes or other disease-associated 
pathomechanisms. 
There are several neurological manifestations in SS, both peripheral and central. 
About 20 to 60% of SS patients present peripheral neuropathies, which include small 
fiber neuropathies, sensorymotor or pure sensory (dorsal ganglion) neuropathies, 
multiple mononeuropathy (mononeuritis multiplex), polyradiculopathy and autonomic 
neuropathy. The neurological symptoms often precede the diagnosis of SS, especially 
in elderly people (Delalande et al. 2004; Chai and Logigian 2010). Central nervous 
system involvement occurs rarely and can lead to diffuse or focal lesions, such as 
subacute aseptic meningitis, chorea, optic neuritis, transverse myelitis etc., but the 
prevalence of those (in range of 8-40%) is difficult to estimate because of use of 
different diagnostic criteria and selection bias. Many patients complain of changes in 
cognitive functions, poor memory and concentration abilities loss (Hietaharju et al. 
1993; Massara et al. 2010). 
SS patients also suffer from gastrointestinal manifestations, caused by motility 
disorders leading to reduced esophageal lower sphincter pressure and disturbed 
peristalsis. Nutcracker esophagus and achalasia have also been reported to be 
associated with SS (Ebert 2012). Dyspepsia, nausea and epigastric pain are 
complaints that SS patients can present. SS can be also associated with primary biliary 
cirrhosis, which is an autoimmune disease characterized by production of 
antimitochondrial and anti-nuclear autoantibodies and clinical cholestatis (Fox 2005; 
Selmi et al. 2012). 
Prevalence of disabling fatigue among SS patients is estimated to be up to 70%. 
Fatigue is often connected to sleep disturbances, muscle pain stiffness and weakness. 
About 27% of the patients fulfil diagnostic criteria for fibromyalgia (Lindvall et al. 
2002). Typical SS patient experiences reduced quality of life and scant social 
activities in advanced stage of the disease due to disturbing systemic symptoms, high-
level anxiety and depression (Meijer et al. 2009). 
Current classification criteria of SS were developed and revised several times since 
1989 by an American-European consensus group (AECG) for SS. The latest most 
widely accepted revision was done in 2002 (Vitali et al. 2002). Inclusion criteria 
combine subjective symptoms of dry eyes and dry mouth with objective ocular and 
salivary signs based on tear- and saliva-flow tests, objective histopathological and 
serological data (Table 1). Simplified criteria have also been suggested and consist of 
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only 2 out of three features, autoantibodies, pathological ocular staining score and 
focal sialadenitis (Shiboski et al. 2012). 
 
Table 1. Inclusion criteria for SS diagnosis (modified from Vitali et al. 2002) 
Items Definition 
I. Ocular symptoms Counts if at least one of the following is fulfilled: 
a. Daily, persistent troublesome dry eyes for more than 3 months. 
b. Recurrent feelings of sand or gravel in the eyes. 
c. Use of tear substitute more than 3 times a day. 
II. Oral symptoms Counts if at least one of the following is fulfilled: 
a. Daily feeling of dry mouth for more than 3 months. 
b. Recurrently or persistently swollen salivary glands as an adult. 
c. Frequent drinking of liquids to aid in swallowing dry food. 
III. Ocular signs Counts if at least one of the following is fulfilled: 
a. Schirmer’s I test ≤ 5 mm in 5 min without anesthesia 
b. Rose bengal score ≥ 4 according to van Bijsterveld’s system 
IV. Histopathology 
      (in minor SG) 
Counts as focal lymphocytic sialoadenitis if focus score ≥ 1, 
defined as number of lymphatic foci per 4 mm2 of glandular 
tissue. 
V. Salivary gland  
     involvement 
Counts if at least one of the following is fulfilled: 
a. Unstimulated whole salivary flow ≤ 1,5 ml in 15 min 
b. Diffuse sialectasis in parotid sialography without evidence of 
major ducts obstruction.  
c. Delayed uptake, reduced concentration and/or delayed 
excretion of tracer in salivary scintigraphy 
VI. Serology Counts if anti-SSA/Ro or/and anti-SSB/La autoantibodies are 
present in the serum  
 
Diagnosis of pSS can be approved if (1) any 4 of the 6 items are positive, as long 
as either item IV (Histopathology) or VI (Serology) is positive, OR (2) any 3 of the 4 
objective criteria items III-VI are positive, OR (3) the classification tree procedure 
represents a valid method for classification, although it should be more widely used in 
clinical-epidemiological survey. 
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Diagnosis of sSS can be approved if in association with another well-defined 
connective tissue disease, the presence of items I or II is supplemented with any 2 
from among items III, IV and V. 
SS diagnosis should be disapproved if patient suspected for SS meets one of the 
following exclusion criteria: past head and neck radiation treatment, hepatitis C virus 
infection, acquired immune deficiency syndrome (AIDS), pre-existing lymphoma, 
sarcoidosis, graft versus host disease, use of anticholinergic drugs (since a time 
shorter than fourfold the half-life of the drug). 
Considering complexity of SS diagnosis many physicians misguidedly treat each 
symptom individually, unaware of the systemic nature of the disease. As usual, early 
diagnosis can provide adequate treatment and improve patient’s wellbeing (Kassan 
and Moutsopoulos 2004). 
 
4.2.2. Current view on aetiology and pathogenesis 
The ultimate cause of SS is not certain, however, presence of a number of signs 
(including biosignatures) of pathological processes discovered in the patients let us 
consider SS as a multifactorial autoimmune disease. Several approaches for SS 
pathogenesis have been proposed so far. The diseased glands are characterized by 
focal lymphocytic infiltration, consisting predominantly of CD4+ T-lymphocytes, B-
lymphocytes and dendritic cells. Histologically the salivary gland in advanced SS 
represents a picture of acinar atrophy associated with ductal hyperplasia. It is assumed 
that ductal epithelial proliferation is a response to the acinar involution process, which 
is due to apoptosis (Voulgarelis and Tzioufas 2010). There are increased levels of 
Th1-response-related proinflammatory cytokines (IL-1β, IL-2, IL-6, IFNγ and TNFα) 
and Th2-response-related antibody-stimulating cytokines (IL-4, IL-5 and IL-13) in 
saliva and serum of SS patients (Roescher et al. 2009). Circulating levels of anti-
SSA/Ro and anti-SSB/La autoantibodies (one of the crucial diagnostic features) as 
well as rheumatoid factor, type-2 cryoglobulins and hypergammaglobulinemia are 
signs of high B-lymphocyte activity in SS (Kallenberg et al. 2011). 
IFNα/β (IFN type I) signature in SS salivary glands, associated with increased 
numbers of IFN-producing plasmacytoid dendritic cells, gives evidence of inductive 
involvement of innate immunity into pathological process of the disease (Ogawa et al. 
2002). This is in line with the up-regulation of IFN type I inducible genes, such as B-
lymphocyte activating factor (BAFF) in SS (Nossent et al. 2008; Lahiri et al. 2014). 
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Various viral infections have been introduced as potential etiological factors for 
SS, because of shared features with the syndrome. However, due to similar 
manifestations, for instance in HCV infection, certain infections are considered, as 
mentioned above, as exclusion criteria for SS diagnosis. The rest, for example 
Epstein-Barr virus, cytomegalovirus, herpes virus-6 and human endogenous 
retroviruses have been proposed to be involved in SS pathological process (Ramos-
Casals et al. 2008; Vitali 2011). 
Hormonal imbalance in SS patients is proposed to be one of the contributing 
elements in the disease. Female dominance among the patients and the age of onset of 
the disease define androgen and estrogen deprivation as one of the key factors 
towards SS development.  According to some studies, low serum levels of DHEA-S 
together with local dysfunction of DHEA processing steroidogenic enzymatic 
machinery in the diseased salivary glands, could lead to local androgen deficiency in 
female SS patients (Spaan et al. 2009). However, DHEA substitution treatment for 
severe fatigue pSS patients in placebo-controlled studies did not have any significant 
healing effect, proposing dysfunction of local androgen synthesis too (Hartkamp et al. 
2008; Virkki et al. 2010). Men, in contrary, a priori have high enough testicle-derived 
systemic levels of androgens, allowing to feed the salivary glands with testosterone, 
which can be sufficiently effectively converted to dihydrotestosterone (DHT), which 
could prevent acinar atrophy and ductal cell hyperplasia caused by local androgen 
deficiency (Porola et al. 2010). 
Oxidative stress along with accumulation of various molecular degradation 
products during aging could contribute to the loss of tolerance and to SS progression. 
Among them dysfunctional Toll-like receptor (TLR), T-cell receptor and B-cell 
receptor signalling as well as age-related changes in dendritic cells and memory B-
cells (Vallejo 2011) are closely intertwined with our current knowledge of SS. 
Altogether these factors in genetically predisposed people can trigger the disease 
and contribute to its progression. Core of the disease is a process of autoantigen 
presentation. It has been suggested that cryptic epitopes of Ro and La 
ribonucleoprotein particles are presented to plasmacytoid dendritic cells complexed 
with adjuvant single-stranded hY-RNA, perhaps via various membrane particles 
(Fabini et al. 2000). Once autoantigen presentation takes place and T-cells are 
polarized and B-cells activated, lymphocytic invasion, resulting in chronic 
inflammatory infiltrates and production of autoantibodies by B-cells, follow. 
 25 
It has been reported that normal apical localization of aquaporin 5 is dislocated to 
basolateral membrane of the acinar cells in SS. Therefore, part of the water destined 
to secretion “leaks” into the interstitium of the salivary gland (Steinfeld et al. 2002). 
Similar phenomenon was also observed in NOD mice, a rodent model of SS 
(Konttinen et al. 2005). 
The etiology and pathogenesis of SS still appears to be a subject for studies and 
detailed analysis. To date, there is no strait and elegant explanation for the disease but 
consensus states that SS is rather a multifactorial and complex autoimmune 
pathological entity.  
 
Table 2. Factors proposed to play role in SS etiopathogenesis* 
Factor Mediators 
Cells Th1, Th17, NK-cells, B-cell, plasma cells, plasmacytoid 
dendritic cells, macrophages, epithelial cells, DN T-cells, 
Th follicular cells 
Cytokines INFα/β, INFγ, TNFα, BAFF, VEGF, IL-1β, IL-5, IL-6, IL-
7, IL-8, IL-12, IL-13, IL-17, IL-18, IL-21, CXCL13, 
CXCL21 
Viruses HIV, Epstein-Barr virus, cytomegalovirus, herpes virus-6 




Polymorphism HLA-II expression (Gottenberg et al. 2003) 
microRNAs, altered methylation 
Autoantibodies SSA/Ro, SS-B/La, α-fodrin, M3 receptor (Bacman et al. 
1996; Ulbricht et al. 2003) 
Aging 
 
Oxidative stress, defective signalling of T-cell receptor 
(TCR), B-cell receptor (BCR) and Toll-like receptor (TLR), 
Adrenopause with a local sex steroid processing 
dysfunction 






Today, management of SS is a challenge for every physician. It is based on 
symptomatic treatment of glandular manifestations and on systemic treatment of 
organ involvement, damage and loss of their function (extraglandular manifestations). 
Symptomatic treatment generally includes measures against sicca symptoms. Dry 
eye topical treatment is based on substitution of tears with artificial hypotonic 
solutions and emulsions that decrease tear film osmolality. Patients are advised to use 
eye drops 3-6 times a day and ophthalmic gels at night. In case of severe dryness, 
topical NSAIDs can be administered for a short time to relieve ocular pain. 
Glucocorticoids, such as dexamethasone drops, can be used to suppress local 
inflammation, but only in severe cases if adviced by a ophtalmologist. Recently, 
ciclosporin A (an immunosuppressive drug) has been reported to be effective in 
topical application for dry eye symptoms and low tear production (Tincani et al. 
2013). There are numerous saliva substitutes available in forms of lubrication gels, 
mouthwashes and sprays for dry mouth relief. Frequent sips of water during 
mastication, use of sugar-free candies, gums or mints are also recommended for SS 
patients. 
Medications mentioned above should be combined with a preventive non-
pharmacological approach, which is based on avoidance of dry, smoky and windy 
environments, prolonged computer work or reading combined with the use of 
humidifiers. Dryness aggravating drugs such as diuretics, beta-blockers, 
antihistamines and drugs with anticholinergic effects should be taken with precautions 
or avoided. Regular oral hygiene procedures should include 0.1% fluoride mouth 
rinse or application of neutral sodium fluoride gel and remineralizing solutions. 
Alcohol, caffeine and fermentable carbohydrates-containing beverages should be 
minimized. Adequate follow-up, individualized treatment and preventive measures 
significantly decrease occurrence of complications. 
Systemic treatment includes limited numbers of different disease-modifying anti-
rheumatic drugs, corticosteroids, immunosuppressive drugs and biologicals. 
Acetycholine receptor agonists in tablets, such as pilocarpine and cevimeline, have 
been shown to be beneficial in the treatment of dry eyes (Mavragani et al. 2006). 
However, use of these pharmacological agents is limited, especially in elderly 
patients, due to side effects including sweating, flushing gastrointestinal discomfort, 
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urinary retention and also because of incompatibility with other diseases such as 
uncontrolled asthma, narrow-angle glaucoma, acute iritis and cardiovascular diseases. 
Musculoskeletal pain and constitutional symptoms in SS patients can be reduced 
by use of NSAIDs. Antimalarial drug hydroxychloroquine has been reported to be 
helpful in patients with systemic features, especially arthritis and skin involvement 
(Kruize et al. 1993; Dawson et al. 2005). Hydroxychloroquine is non-applicable to 
patients with renal failure and retinal damage (Rigaudiere et al. 2004). SS patients can 
be treated with low-dose prednisone eqvivalent  up to 10 mg/day. With first signs of 
necrotic or ulcerating vasculitis, the daily prednisone dose should be increased up to 
30 mg/day. In case of severe manifestations like life-threatening central nervous 
system or progressive renal failure, high-dose corticosteroids (1 mg/kg daily) in 
combination with cyclophosphamide can be administered (de Seze et al. 2006). 
Many pharmacological reagents that initially looked promising in SS trials have 
shown very modest efficacy or had no healing effect at all. Antimetabolite 
methotrexate showed improved subjective parameters, but no improvement of 
objective signs in patients with sSS and additionally had adverse effects (Group 
1995). Despite positive symptomatic treatment results in RA, high prevalence of 
adverse effects and inefficiency in SS have been reported for azathioprine and also 
sulfasalazine (Price et al. 1998; Thanou-Stavraki and James 2008). IFNα therapy in 
randomized controlled trials showed a controversial outcome. There was no 
significant effect on oral dryness or stimulated whole salivary flow, however, non-
stimulated salivary flow increased in SS patients (Cummins et al. 2003; Shiozawa and 
Shiozawa 2006). On the contrary, recently finished anti-IFNα therapy clinical trials 
with immunogenic interferon-α-kinoid in patients with SLE showed significant down-
regulation of IFN signature (Lauwerys et al. 2013). Several biologicals targeting 
TNF-α, including infliximab and etanercept, have been reported to be ineffective in 
trials with SS patients (Mariette et al. 2004; Zandbelt et al. 2004). Rituximab has been 
reported to be helpful in SS. Administration of this chimeric monoclonal antibody 
specific for CD20 B-cell surface molecule has been tentatively shown to improve both 
subjective and objective symptoms at least for 6-9 months in patients with active pSS 
in randomized controlled trials and in open-label studies (Devauchelle-Pensec et al. 
2007; Dass et al. 2008; Pijpe et al. 2009; Meijer et al. 2010), but it did not improve 
salivary flow in patients with no or almost no residual salivary flow at baseline. 
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Open-label study has shown promising results for epratuzumab, a humanized 
monoclonal antibody, which is specific for CD22 B-cell surface protein. Use of the 
drug resulted in improvement of objective signs and in visual analogue scale scores 
for fatigue (Steinfeld et al. 2006). 
DHEA was proposed as a potential drug for SS patients, because of female 
dominance. However, as mentioned above, it had no healing effect in the controlled 
trials. 
SS patients are vulnerable to oral candidiasis with a prevalence up to 30-70%, 
especially after treatment with corticosteroids and antibiotics. Depending on 
localization, topical or systemic antifungal drugs are usually administered (Soto-Rojas 
and Kraus 2002). 
So far, symptomatic approach still remains fist line treatment for SS patients, due 
to lack of evidence on aetiology and complete knowledge on the pathogenesis of SS. 
Recent trials have shown some tentative beneficial effects of biologicals targeting B-
lymphocyte-mediated and IFN type I-mediated responses. Other potential targets in 
pathogenetic-directed treatment include BAFF and cytokines like IL-6, adhesion 
molecules and chemokines (Moerman et al. 2013). 
 
 
4.3. Histamine metabolism and transport  
 
4.3.1. Histamine producing cells and “on/off-state” conception 
Histamine is a biogenic amine, perhaps one of the most intensively studied 
inflammatory mediators, which participates in many pathological events, including 
processes in allergy and autoimmune diseases. Although histamine-producing cells 
vary considerably in origin and functions, they can be classified under two types, 
professional and non-professional histamine producing cells. Professional histamine 
producing cells synthesize rapidly, store in granules and release in bursts histamine 
into the extracellular milieu so that local histamine reaches high micromolar 
concentrations. Unlike professional, non-professional histamine producing cells 
synthesize histamine continuously at low speed, do not store it in granules and 
transfer it between the intracellular and extracellular space along its concentration 
gradient via “equilibrative uniporter” channels. This leads to a rather low local 
nanomolar histamine concentration. Such a dichotomy of histamine secretory cells is 
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connected to a similar dichotomy in the histamine affinity of histamine receptors and 
their involvement in certain pathological/physiological events (Konttinen et al. 2013). 
In general, low-affinity conventional H1R and H2R are maximally active in allergy 
and helminthic infections, leading to usually rather acute and transient conditions 
which may suffice to eliminate most of the allergen and parasitic irritants. From this 
point of view, it is natural that professional the histamine producing cell group 
comprises mobile basophils and tissue resident mast cells throughout the body, which 
can be recruited and activated upon need, resulting in their degranulation. 
Enterochromaffin-like cells (ECL) of the gastric mucosa, which take a prominent part 
in food digestion via activation of H2R, can be included in the professional histamine 
producing cell group. In turn, high-affinity histamine receptors, in particular the novel 
H4R, seem to maintain and regulate subtle underlying mechanisms responsible for 
homeostasis and tolerogenic immunity. Accordingly, the non-professional histamine 
producing cell group includes many cells involved in immune responses, namely 
dendritic cells, T-cells and monocytes/macrophages (Kubo and Nakano 1999; 
Szeberenyi et al. 2001; Tanaka and Ichikawa 2011). These findings suggest a novel 
role for histamine in immune coordinated actions, which became a hot topic last 
decade. In addition, non-immune cells, such as foetal liver cells, ductal epithelial cell 
of the salivary glands, epithelial cells of the mammary glands, skeletal muscle cells 
and even sperm cells produce histamine at low concentrations (Tanaka and Ichikawa 
Figure 2. Histamine producing cells during off- and on-state. 
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2011; Niijima-Yaoita et al. 2012), which may help to maintain the immunological 
tolerance. 
As well as being the main source of local nanomolar concentration of histamine 
during so-called “off-state” phase, non-professional histamine producing cells assume 
another function of being high-capacity histamine sinks, when MCs or other 
professional histamine-producing cells release vast amounts of histamine during 
short-term “on-state” phase (Figure 2).  Subsequently, the intracellular histamine-N-
methyl transferase (HNMT)-dependent degradation of histamine preserves cells from 
excessive overstimulation and brings back homeostatic histamine quantity to the 
milieu. 
A part from a number of histamine producing cells, food, such as various fish and 
vegetables, is also a source of histamine (Maintz and Novak 2007). Studies show, that 
histidine decarboxylase (HDC) knock-out mice are not totally “histamine-free”, even 
when kept on histamine-free diet (Ohtsu et al. 2001; Mondillo et al. 2007). In that 
sense, microbial intestinal flora, in particular species from Lactobacillaceae and 
Enterobacteriaceae families, plays a role as a minor histamine supply depot (Riley 
and Snell 1968; Devalia et al. 1989; Ohtsu et al. 2002). 
 
 
4.3.2. Histamine synthesis, release, transport and degradation  
Histamine is synthesized by histidine decarboxylase (HDC), the exclusive 
histamine synthesizing enzyme, which catalyses conversion of the amino acid L-
histidine to histamine with vitamin B6 as a cofactor (Rosenthaler et al. 1965) (Figure 
3). The molecular mechanisms underlying professional and non-professional 
histamine synthesis have its explanation in the existence of two cleavage isoforms of 
Figure 3. Histamine synthesis (simplified). 
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HDC: (1) low active full-length 74-kDa HDC and (2) high active cleaved 53-kDa 
HDC. Both of them are found in mammalian cells, but in different subcellular 
compartments. In non-professional histamine producing cells 74-kDa HDC is 
localized in the cell cytoplasm, whereas in professional histamine producing cells it is 
cleaved by caspase-9 in the endoplasmic reticulum (ER) and subsequently localized to 
the granule fraction, where it rapidly synthesizes vast amount of histamine in about 
100-1000-fold higher speed than the 74-kDa HDC (Ichikawa et al. 2010). HDC 
activity varies in different conditions, like inflammation, under stimulation by 
cytokines, such as IL-1, IL-3, IL-12, IL-18, GM-CSF and TNFα (Jutel et al. 2009).  
At the physiological pH values (≈7.36) histamine is a positively charged amine 
(monovalent cation). In non-professional histamine producing cells de novo 
synthesized histamine passes freely along concentration gradient from cytoplasm to 
extracellular space (or vice versa) via plasma membrane organic cation transporters 
(OCTs), OCT2 and OCT3, also known as solute carriers SLC22A2 and SLC22A3, or 
via plasma membrane monoamine transporter PMAT, also known as SLC29A3 and 
as equilibrative nucleoside transporter ENT3. These pH-dependent equilibrative 
uniporters do not utilize chemical ATP energy and can transport other monoamines 
like serotonin, dopamine and some drugs (Grundemann et al. 1999). This mechanism 
of secretion/release allows cells to achieve extracellular histamine nanomolar-, but not 
higher concentrations, which are only effective via H3R and H4R, based on their high 
histamine affinity reflected in their pKi values of 8.0 and 8.2 respectively (Konttinen 
et al. 2013). 
Professional histamine producing cells release histamine in a burst-like manner by 
exocytosis. Degranulation occurs in sensitized individuals when mast cell or basophil 
surface IgE is effectively cross-linked by allergen (immediate type I hypersensitivity). 
Such rapid release leads almost immediately to micromolar histamine concentrations, 
which act effectively on H1R and H2R (their pKi values are 4.2 and 4.3 respectively). 
ECL-cells rapidly release histamine either upon direct acetylcholinergic stimulation or 
indirectly via D-cell-mediated somatostatin stimulation. Professional cells, like mast 
cells, also express OCT3, which can serve as a way for histamine recirculation into 
these cells. Once histamine is re-uptaken, it is further transported back to the storage 
granules via vesicular monoamine transporter 2 (VMAT2), also known as SLC18A2. 
Via VMAT2 also newly synthesized histamine passes from 53-kDa HDC into the 
storage granules. High amounts of histamine can be further washed away by body 
 32 
fluids and is degraded extracellulary, or is taken up by non-professional histamine 
producing cells via already mentioned equilibrative solute carriers for further 
intracellular degradation. These processes are catalysed by two major histamine-
degrading enzymes: diamine oxidase (DAO) and histamine-N-methyl transferase 
(HNMT) (Maintz and Novak 2007) (Figure 4). DAO metabolizes extracellular 
histamine (15-30%) to imidazole-4-acetaldehyde, which is subsequently transformed 
into imidazole acetate by aldehyde dehydrogenase. Studies show that DAO is released 
into extracellular space from vesicles located close to cell membrane upon appropriate 
stimulation (Maintz and Novak 2007). Mammalian DAO has been shown to be 
expressed mostly in small intestine, ascending colon, placenta and in  renal tubular 
cells. HNMT appears to be the only intracellular histamine-degrading enzyme. It 
metabolizes the majority of histamine (50-80%) to N-methyl histamine, which is 
further metabolized by monoamine oxidase to M-methylimidazole, the primary 
urinary metabolite. HNMT is present in many epithelial cells, in particular in airway 
epithelium, where it is responsible for local histamine degradation released from mast 
cells (Barnes et al. 1985; Sekizawa et al. 1993). In mammals HNMT is also expressed 
in gastrointestinal tract, urinary bladder, islets of Langerhans, epidermal cells of the 
skin and in kidney tubules (Tahara et al. 2000). Altered expression or absence of 
DAO in the tissues together with exposure to high enough histamine may result in 
histamine intolerance. Impaired enzymatic activity can be due to genetic reasons or 
Figure 4. Histamine degradation (simplified). HNMT = histamine-N-methyl transferase, DAO = 
diamine oxidase. SAM = S-adenosylmethionine, SAHC = S-adenosylhomocysteine.  
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acquired in competitive inhibition by other biogenic amines from food (Sattler et al. 
1988), alcohol or drugs (Sattler and Lorenz 1990; Wantke et al. 1994). Reduced 
HNMT activity is highly associated with asthma and other respiratory diseases 
(Nakazawa et al. 1994; Preuss et al. 1998).  
 
 
4.4. Histamine receptors 
 
For the first time multiple effects of the histamine (β-iminazolylethylamine) were 
described more over than a century ago (Dale and Laidlaw 1910). However, the 
description of the receptors came along with the first generation antihistamines (Ash 
and Schild 1966). Due to selective inhibition of some of the histamine-mediated 
effects, the existence of several types of histamine receptors was proposed. Later, the 
genome sequencing technologies have confirmed the empirical knowledge of 
different types of histamine receptors. For the time being, four types of histamine 
receptors have been identified. Their characteristics are briefly depicted in table 3. 
 
Table 3. Characteristics of the histamine receptors, modified from Shahid et al., 2009 
Characteristics H1R H2R H3R H4R 
 
a,b Receptor described, 
human gene cloned 
 





dpKi to histamine 
 



















Ca2+ , cGMP, 
NF- B, PLC , 
phospholipases 
A2 and D, 















cAMP , Ca2+ ,  















Ca2+ ,  















Ca2+ ,  
MAP kinase , 
cAMP  
 
cAMP = cyclic adenosine monophosphate, cGMP = cyclic guanosine monophospate, MAP = mitogen-activated 
protein, NF- B = nuclear factor- B, NOS = nitric oxide synthase, PLC = phospholipase C. *splice variants 
a(Simons 2004), b(MacGlashan 2003), c(Dy and Schneider 2004), d(Thurmond et al. 2008) 
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4.4.1 Histamine H1 Receptor 
H1R is the best known histamine receptor. It is widely expressed in smooth muscle 
cells of airways, endothelial cells of blood vessels, central nervous system, 
chondrocytes, myeloid cells, such as monocytes, neutrophils, dendritic cells and also 
in T- and B-lymphocytes, gastrointestinal tract, heart, genitourinary system and 
adrenal medulla. In disease states this receptor mediates different aspects of type I 
allergic reaction, which includes redness, itching and swelling, so called “triple 
response”. Allergy is a typical pathological process, which occurs in many different 
forms, including allergic rhinitis, atopic dermatitis, conjunctivitis, urticaria, asthma, 
anaphylaxis etc. H1R has been shown to be involved in all these conditions. H1R-
mediated high levels of histamine cause bronchoconstriction, enhanced vascular 
permeability of capillary vessels and vasodilatation, modulation of immune-
inflammatory responses via eosinophils, basophils and other already mentioned 
immune cells (Akdis and Blaser 2003; Togias 2003; Haas et al. 2008; Huang and 
Thurmond 2008; Simons 2008; Feng et al. 2013).  H1R activation causes series of 
various cellular responses, like expression of adhesion molecules on vascular 
endothelial cells, synthesis of prostacyclin, platelet-activation factor, release of von 
Willebrand factor and nitric oxide (NO) (Svensjo and Grega 1986; Hamilton and Sims 
1987; Carter et al. 1988; Kishi et al. 1996; Li et al. 2003). Studies have shown that 
histamine can stimulate release of adrenaline and noradrenaline from adrenal medulla 
and induce phosphorylation of tyrosine hydroxylase via H1R (Livett and Marley 1986; 
Bunn et al. 1995). The majority of these phenomena are due to activation of 
phospholipase C (PLC) upon binding histamine or other H1R-agonist to the receptor. 
Gαq/11–protein subunits activate PLC, which in turn generates inositol 1,4,5-
trisphosphate and 1,2-diacylglycerol leading to increased cytosolic Ca2+ levels and 
activation of protein kinase C. Enhanced Ca2+ triggers many pathways including NO 
production, release of arachidonic acid from phospholipids and increased production 
of cAMP and cGMP (Smit et al. 1999). H1R stimulates nuclear factor kappa B 
(NFκB) leading to production of pro-inflammatory cytokines (Leurs et al. 1995). 
First generation of antihistamines (Mepyramine, Diphenhydramine, Doxylamine, 
Pheniramine, Cyclizine, etc.) has many adverse effects. Dry mouth, orthostatic 
hypotension, increased appetite, disturbances of circadian and cardiac rhythms and 
disturbed locomotive activities occurred in patients who were treated with H1-
antihistamine therapy. This was due to their non-selective effects on muscararinic, α-
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adrenergic and serotonin receptors and unwanted effects in the CNS. Today, new 
generation of antihistamines, which cannot cross the blood-brain barrier, have been 
designed and taken into use (Loratadine, Ketotifen, Cetirizine). First generation 
compounds with sedative effects are used mostly for treatment of allergy in 
association with sleep disturbances and cyclical vomiting syndrome 
(Cyproheptadine), but also for preoperative sedation and to counteract postnarcotic 
nausea (Andersen et al. 1997; Lehmann et al. 2013). 
 
4.4.2. Histamine H2 receptor 
H2R has gained a lot of attention when its gastric localization was discovered. The 
receptor is expressed in parietal cells in gastric mucosa, where histamine/H2R ligation 
stimulates secretion of hydrochloric acid, when histamine is released from ECL-cells 
localized nearby. H2R is also expressed in many immune cells, including neutrophils, 
eosinophils, monocyte/macrophages, dendritic cells, T- and B-lymphocytes. In these 
cells H2R often has actions opposite to those of H1R. For example, activation of H2R 
results in inhibition of T-cell proliferation, cell-mediated cytolysis and cytokine 
production (Melmon and Khan 1987; Hill 1990; Jutel et al. 2001; Gutzmer et al. 
2005). H2R activation diminishes eosinophil and neutrophil chemotaxis and polarizes 
immune responses from Th1/M1-type cell-mediated direction to Th2/M2-type by 
inducing DC2s and humoral immunity (Simons 2004). H2R is found on epithelial-, 
endothelial- and smooth muscle cells of blood vessels, bronchioles and bowel. It 
increases vascular permeability, increases production of mucus and causes 
bronchodilatation and relaxation of uterine muscle (Eyre and Chand 1982; Edvinsson 
et al. 1983; Ottosson et al. 1989; Simons 2004). It has been reported that in cardiac 
tissues H2R mediates positive chronotropic (rate of contractions) and inotropic 
(strength of contraction) effects, whereas H1R activation slows down heart rate 
(Genovese et al. 1988). Expression of both H1R and H2R in CNS has been 
documented and overlaps in such areas as hippocampus, thalamus, cerebral cortex, 
with a low expression in cerebellum. Hypothalamus is mostly H1R positive, whereas 
H2R prevails in the basal ganglia.  
Signalling of H2R is predominantly mediated by cyclic AMP-producing adenylate 
cyclase second messenger system via a GTP-dependent mechanism. In turn, cyclic 
AMP activates a multiple substrate-oriented phosphorylating enzyme, protein kinase 
A (PKA), which results in certain cell responses (Shahid et al. 2009). Studies have 
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shown that H2R stimulation results in elevated intracellular Ca2+ levels via inositol 
trisphosphate (Delvalle et al. 1992). However, this phenomenon cannot be reproduced 
in H2R-trasfected cells, suggesting that H2R/Ca2+-mediated signalling mechanism is 
highly cell-specific (Leurs et al. 1994). Activation of H2R stimulates c-Fos, c-Jun and 
p70S6 kinase (Dy and Schneider 2004; Jutel et al. 2009). 
The introduction of H2R antagonists together with PPI led to important changes in 
the treatment of gastric and duodenal ulcer and gastro-esophageal reflux disease. 
Surgical treatments, such as gastric resections, with or without vagotomy, were 
successfully replaced with gastric acid production inhibiting compounds. Fortunately, 
these drugs have only a small number of CNS-derived adverse effects limited to 
vertigo, and more rarely headache based on postsynaptic expression pattern of H2R 
(Haas et al. 2008). Inhibitory effects of H2R antagonists, especially cimetidine, on the 
cytochrome P450 system in liver may cause interaction with other drugs, which are 
metabolized by this enzymatic machinery (Levine et al. 1998). Due to a competitive 
affinity to dihydrotestosterone (DHT) receptor, such adverse effects like galactorrhea 
in women and gynecomastia in men were reported for cimetidine use in a long-term 
treatment (Sawyer et al. 1981; Sabesin 1993). Later synthesized and marketed drugs 
(Famotidine, Lafutidine etc.) have solved the problem of exaggerated hormonal 
adverse effects, but elevated risks of developing food allergies and constipation or 
diarrhea, due to suppressed acid-mediated breakdown of proteins, have been reported 
(Pali-Scholl and Jensen-Jarolim 2011). 
 
4.4.3. Histamine H3 Receptor 
The highest density of H3R expression is observed in CNS, with highest levels in 
basal ganglia, cortex, hippocampus and striatal area. Involvement of histaminergic 
neurons in sleep-awake cycle, energy homeostasis and cognitive processes has 
attracted the researches to study the possible role of histamine in the pathogenesis of 
various mental disorders. Functional relationships between H3R-positive mast cells 
and peripheral histaminergic neurons, which originate from the tuberomamillary 
nucleus, suggest a role for H3R in immunomodulation (Dimitriadou et al. 1994; Haas 
and Panula 2003; Haas et al. 2008). A recent study has shown that presynaptically 
located H3R activates negative feedback mechanisms, which result in inhibition of 
histamine from neurons (Teuscher et al. 2007).  Activation of H3R inhibits release of 
a number of other neurotransmitters, such as acetylcholine, serotonin, noradrenaline 
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and dopamine (Schlicker et al. 1989; Molderings et al. 1992; Schlicker et al. 1992; 
Schlicker et al. 1993). Prominent inhibitory effect of H3R on release of tachykinins 
(substance P, neurokinin A, neurokinin B) and calcitonin-gene related peptide 
(CGRP) has been discovered in a number of peripheral tissues (Delaunois et al. 1995; 
Imamura et al. 1996). It was proposed that in gastric mucosa H3R is expressed in local 
mast cells or ECL cells, inhibiting professional burst-like histamine release and 
therefore gastric acid secretion (Soldani et al. 1993). On the other hand, in vitro 
studies show that H3R stimulation leads to adrenocorticotropic hormone release from 
a pituitary cell line (Clark et al. 1992). Interesting observations have been made on 
H3R knock-out mice. These animals exhibited increased body weight, due to 
increased food intake and reduced energy consumption. It is in line with the data of 
up-regulated insulin and leptin resistance and down-regulated expression of energy 
homeostasis-assosiated genes UCP1 and UCP3 (Rouleau et al. 2002; Takahashi et al. 
2002). 
Mechanism of H3R action is still the matter of scrupulous studies, but there is 
increasing evidence of Gi/o protein-dependent mechanism for being responsible for the 
receptor action. H3R activation leads to inhibition of cyclic AMP production, 
accumulation of Ca2+ and stimulation of mitogen-activated protein kinase (MAPK) 
pathways (Cherifi et al. 1992; Dimitriadou et al. 1994). 
To date, there are no commercially H3R modulators available for routine treatment. 
Patients with allergic disorders, mental and CNS degenerative diseases have entered 
phases II-III controlled clinical trials of H3R inverse agonist. (Passani and Blandina 
2011). Trials and validation of the results are still going on. For example, Pitolisant 
(BF2.649) has been granted orphan drug status in the EU and USA for the treatment 
of narcolepsy (van der Heide et al. 2015). Another compound, known as PF-
03654746 has shown promising results in treatment of allergen-induced nasal 
symptoms in combination with second-generation antihistamine fexofenadine (Stokes 
et al. 2012). GSK239512 improved episodic memory in patients with mild-to- 
moderate Alzheimer's disease, however, no improvements were observed on 
executive function/working memory or other domains of cognition (Grove et al. 
2014). Unfortunately H3R modulatiors were not superior to placebo in the treatment 
of cognitive impairment in patients with schizophrenia (M et al. 2013; Haig et al. 




4.4.4. Histamine H4 receptor 
The pharmacological discovery of H4R was done over 20 years ago when 
nanomolar doses of histamine were shown to increase intracellular Ca2+ in eosinophils 
about 7.5-fold more effectively in comparison to specific H3R agonists R-MeHA and 
N-MeHA (Raible et al. 1994). Later, several groups have cloned the H4R protein in 
different cell lines (Nakamura et al. 2000; Oda et al. 2000; Liu et al. 2001; Nguyen et 
al. 2001; Zhu et al. 2001). Since then, H4R has become a hot topic but still rather little 
is known of the biological function of the receptor. Localization of H4R is relatively 
restricted to hematopoietic cells, in particular to eosinophils, neutrophils, basophils, 
mast cells, NK-cells, dendritic cells and T-lymphocytes (Damaj et al. 2007). This 
expression in both myeloid and lymphoid lineages proposes an important role in 
inflammation and immune responses. Functional studies show recruitment of 
neutrophils from bone marrow upon H4R activation (Takeshita et al. 2003). H4R-
mediated diminished production and secretion of CCL2 chemokine in monocytes 
(Dijkstra et al. 2007). There are some studies reporting H4R-mediated chemotactic 
activity in mast cells, eosinophils (Buckland et al. 2003; Hofstra et al. 2003; Ling et 
al. 2004) and human monocyte-derived dendritic cells along with suppression of IL-
12p70, an important NK-cell activator (Gutzmer et al. 2005). CD8+ T-killer cells 
show histamine/H4R-dependent release of IL-16, a chemoattractant and T-cell 
modulator (Gantner et al. 2002).  
Apart from the hematopoietic cells, low-density expression of H4R has been shown 
in central and peripheral nervous systems, which however is still the matter of 
debates. The receptor was found in neuronal cells of nasal mucosa (Nakaya et al. 
2004), anterior horn of the spinal grey matter and dorsal root ganglia in mice, 
suggesting expression in  lower motor and primary sensory neurons, respectively 
(Kajihara et al. 2010; Lethbridge and Chazot 2010), in primary vestibular neurons in 
rat (Desmadryl et al. 2012), in enteric neurons in the Meissner’s submucosal neural 
network (Breunig et al. 2007), somatosensory cortex in mice and other parts of CNS 
of rodents and humans (Zhu et al. 2001; Connelly et al. 2009; Strakhova et al. 2009). 
There are some reports about H4R expression in other types of cells, such as skin 
fibroblasts and keratinocytes, fibroblast-like type B and macrophage-like type A 
synovial lining cell, chondrocytes (Yamaura et al. 2013) and osteoclasts (Biosse-
Duplan et al. 2009).  
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Studies of regulation of H4R expression are in progress. Genomic-based approach 
of the human H4R with detailed promoter region mapping has revealed several 
binding sites including those for ISRE, IRF-1, NF-κB and NF-IL-6. This finding 
predicts that H4R receptor gene expression might be stimulated by factors such as 
IFN, TNF-α or IL-6 (Coge et al. 2001). Recent in vitro studies showed interferon- and 
micromolar histamine-dependent down-regulation of H4R mRNA expression in oral 
epithelial cell (Salem et al. 2015). Furthermore, IL-10 and IL-13 have been shown to 
down-regulate H4R expression in monocytes, Th2 and dendritic cells (Morse et al. 
2001). This intriguing interplay between inflammatory and anti-inflammatory factors 
with H4R may have cellular phenotype-dependent implications on the immune 
network. 
 H4R is implicated in cancer- and cell cycle-related processes. Selective activation 
of H4R in vitro in human cancer cells of different origin suggests anti-proliferative 
effects, which has been demonstrated in pancreatic carcinoma cells (Cricco et al. 
2008), breast cancer cells (Medina et al. 2008) and melanoma cells (Massari et al. 
2011; Massari et al. 2013). This effect is apparently due to cell cycle arrest at G0/G1 
and/or G1/S stages without signs of apoptosis (Petit-Bertron et al. 2009). Only human 
breast cancer cells in vitro and in vivo (heterologous injection into mouse) went into 
apoptosis (Medina et al. 2011; Martinel Lamas et al. 2013). The most intriguing 
results on H4R activation have been reported in rodents in in vivo models of radiation-
induced apoptosis. In all experiments 0.1 mg/kg histamine reduced apoptosis and 
preserved the function of mice bone marrow cells (Medina et al. 2010), mice 
submandibular salivary gland epithelium (Medina et al. 2011) rat uterus and both 
mice and rat small intestinal mucosa (Medina et al. 2007; Carabajal et al. 2012).  
Similar results in rats with diminished intestinal mucosal atrophy, reduced bone 
marrow aplasia and reduced salivation and atrophy and reduced apoptosis of cells in 
SMG were observed when 10 mg/kg JNJ7777120 was administered (Martinel Lamas 
et al. 2013). JNJ7777120 is a H4R ligand with a biased signalling, exhibiting both 
partial agonism or reverse agonism in different biological native systems (Rosethorne 
and Charlton 2011; Seifert et al. 2011). 
Being coupled to Gi/o-protein H4R initiates various transduction pathways such as 
inhibition of cAMP formation, MAPK phosphorylation, in particular of ERK1/2 
(Massari et al. 2013), enhanced calcium influx and formation of diacylglycerol 
(DAG) (Oda et al. 2000; Zhu et al. 2001). Although H4R is 43% homologous with 
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H3R (Morse et al. 2001) and their signalling characteristics are similar, their actions 
can overlap but also contradict each other, as shown in the case of in vitro H3R-
induced apoptosis (Cricco et al. 2008; Medina et al. 2008). In the cellular networks 
H3R/H4R co-actions seem to be in balance, perhaps in part due to different cellular 
expression profiles (Nguyen et al. 2001; Shi et al. 2012). 
Since the discovery of H4R numerous ligands were synthesized and proposed as 
potential drugs targeting the receptor. Some of these compounds have been tested in 
vivo. For example, the use of JNJ7777120 in animal models of peritonitis suggests a 
potential role for the compound in the treatment of inflammation (Thurmond et al. 
2004).  
Several compounds with a pyrimidine moiety have entered into clinical trials. 
Among them H4R antagonists UR-63325 (Palau Pharma) and ZPL-38937887 (Ziarco 
Pharma) showed promising results in phase I studies of allergic respiratory diseases. 
However, JNJ39758979 (Johnson and Johnson) did not pass phase II trial and has 
been withdrawn due to agranulocytosis (Salcedo et al. 2013). Compound INCB38579 
(Incyte Corp.) has shown potential therapeutic value in preclinical studies in the 
treatment of dermatological diseases (Shin et al. 2012). 
 
4.4.5. Constitutive receptor activity 
A widely accepted two-state model of receptor activation describes ligand-receptor 
interactions for H4R and many other G-protein coupled receptors (GPCRs) (Leff 
1995). The model predicts the existence of the receptor in two isomeric states, resting 
or ground state (R, GDP-bound) and active state (R*, GTP-bound). Most receptors 
assume the resting (non-signalling) ground state in the absence of ligand. Some 
receptors may in part assume the activated (signalling) state in the absence of ligand. 
This means that the receptor has some intrinsic constitutive activity. In the absence of 
ligand the distribution of the two states is determined by the equilibrium constant. 
The binding strength of the ligand to its receptor is referred to as affinity, whereas the 
effects of this binding on the receptor and its associated signalling system are referred 
to as efficacy. A ligand has affinities to both states of the receptor. If affinity of the 
ligand is higher to receptor’s active state, ligand is called an agonist (positive 
efficacy), as the receptor/G protein coupling shifts the equilibrium towards R*, 
followed by subsequent signal transduction. If the affinity of the ligand is higher to 
the resting state, it is called an inverse agonist (negative efficacy), as coupling shifts 
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the equilibrium towards R and constitutive receptor activity in inhibited. If coupling 
does not affect the R-R* equilibrium, the ligand is called a neutral antagonist (zero 
efficacy) or a blocker. It possesses equal affinity to both R and R* states, so it 
competes with the agonists for the receptor binding sites without having any influence 
on response when applied alone. Affinity is an ability of the ligand to bind to the 
receptor by non-covalent intermolecular interactions. Mathematically affinity can be 
expressed using the receptor-ligand (AR) dissociation constant Kd=[A]×[R]/[AR]. The 
ratio Kd:Kd* is efficacy and defines the extent of the effect of the ligand. When Kd:Kd* 
>1, the ligand behaves as an agonist; when Kd:Kd* <1 the ligand behaves as inverse 
agonist; when Kd:Kd* =1, the ligand is considered a neutral antagonist (Figure 5, A). 
In case of H-receptors, histamine is a conventional physiological full agonist, whose 
efficacy is defined as 100%. Upon pharmacological studies of H-receptors, compound 
thiopyrimidine (THIO) has been considered a full inverse agonist for H1R, whose 
efficacy is defined as –100%. Subsequently this definition was later applied to other 
discovered H-receptors, including H4R. The efficacies of all newly synthesized 
potential H-receptor ligands are calculated based on the conventional reference means 
of histamine and thiopyrimidine (Figure 5, B). 
Some receptors spontaneously adopt R* state and promote G-protein signalling in 
the absence of agonist, which is referred to as constitutive or basal activity. H4R 
possesses extraordinary high constitutive activity, especially in comparison to H1R 
and H2R, constitutive activity of those is moderate and low-moderate (Seifert and 
Figure 5. A: Two-state model of H4R activation. IA= inverse agonist, A= agonist. Kd= dissociation 
constant, L= equilibrium constant. The model shows shifted equilibrium towards active H4R* form, 
representing high constitutive (basal) activity of the receptor. (Modified from Leff 1995) 
B: Functional binding assay with [35S]GTPγS on membrane preparation of Sf9 cells expressing 
hH4R, co-expressed with Gai2 and Gb1c2 subunits. (Modified from Sander et al. 2009, to show 
efficacies of different ligands) 
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Wenzel-Seifert 2002). The studies show that the active-state H4R* is insensitive to 
high Na+ (100 mM) concentrations, so called ionic lock, which plays role in affecting 
access to the binding site. H4R also exhibits low G-protein activation kinetics, that 
suggests sustained and prolonged responses to histamine under physiological 
conditions and in long-term inflammatory processes. This is in line with report on the 
existence of human H4R in a G-protein-independent high-affinity conformation 
without mammalian G-proteins in transfected cells. Interestedly, histamine and THIO 
do not affect H4R expression, but cause conformational stabilization, unlike many 
other inverse agonists and neutral antagonists, which up-regulate specific receptors. 
Therefore it is suggested that inverse agonists refold denatured receptors, leading to 
increasing number of the binding sites without increasing the number of receptors on 
the cell membrane. In addition to this so-called “functional up-regulation”, changes in 
glycosylation pattern, which is important for the cell surface expression of histamine 
receptors, is suggested to play a regulatory role for the constitutive activity (Schneider 
et al. 2009). 
 
 
4.5. Histamine and salivary secretion 
 
The first report on presence of histamine in salivary glands extracts from 
vertebrates and invertebrates appeared over 60 years ago (Erspamer and Boretti 
1951). Later, discovery of H1R in 1966 and H2R in 1972 entailed new era of 
histamine research and first generations of antihistamines were synthesized. Before 
discovery of H3R and H4R, all findings of histamine effects on the salivary glands 
were considered only through H1R and H2R. Production of saliva comprises two 
simultaneously ongoing responses: salivary response, which is defined by contraction 
of myoepithelial cells expelling the secretions into the ductal system of the gland, and 
blood flow response, defined by local vasodilatation, due to vascular smooth muscle 
relaxation. Involvement of histamine to these responses was assumed and proposed by 
a number of researches (MacKay 1927; Babkin and Mackay 1931; Gibbs and 
McMlanahan 1937; Emmelin 1966). It was later shown that both responses are 
sensitive to histamine, that caused increased salivary and blood flow in dog salivary 
glands (Shimizu and Taira 1980). The authors reported decreased salivary response to 
histamine in the presence of Na+-channel blocker tetrodotoxin and M-acetylcholine 
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receptors blocker (–)-hyoscyamine, suggesting that the motor effect of histamine on 
myoepithelial cells might be indirect via excitation of innervating parasympathetic 
nerves. A direct effect of histamine on myoepithelial cells was not observed, which 
contradicted some earlier findings (Babkin and Mackay 1931). The blood flow 
response, however, was resistant to any of the used M- and N-acetylcholine receptors 
blockers, H2-receptor blocker (metiamide), but was sensitive to H1-receptor antagonist 
mepyramine. This result suggested a direct dilatation effect of histamine on vascular 
smooth muscle rather than stimulation of parasympathetic postganglionic neurons. 
Salivary response to histamine was abolished in 15 min after mepyramine infusion. It 
was concluded that the leading role of histamine in the regulation of both salivary and 
blood flow response is H1R-mediated. To our knowledge, since then and after the 
discovery of H3R and H4R, no reports visualizing H-receptors by immunostaining in 
human salivary glands have been published. 
Despite the fact that ductal epithelium contains only about 10% of all salivary 
gland histamine (Erjavec 1985), local histamine concentration (2.8-112.7 nmol) (Kejr 
et al. 2010) is sufficient to half maximally activate highly sensitive H3R and H4R 
(pKi H3R = 7.8, pKi H4R = 8.1) (Thurmond et al. 2008). The rest of histamine is stored 
in the mast cells, the number of which positively correlates with the focus score count 




4.6. Apoptosis and its role in SS 
 
Apoptosis is a physiological programmed cell death in multicellular organism. 
Billions of cells die by apoptosis every day in adult humans. The term apoptosis 
derives from the Greek word ἀπόπτωσις meaning “the falling-off leaves”. It was 
introduced by Kerr with co-authors in 1972 (Kerr et al. 1972). This built-in cell death 
mechanism is essential in biological processes such as embryonic development, 
elimination of dangerous autoreactive T- and B-lymphocytes in the lymphatic nodes 
and maintenance of a ready supply of short-lived neutrophils in the bone marrow, 
which can be rapidly mobilized to fight infection. Cells with non-repairable damaged 
DNA usually kill themselves by undergoing apoptosis. In adult tissues, the apoptotic 
process is in a balance with cell division. Enhanced and rapid apoptosis usually leads 
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to atrophy. Reduced apoptosis, however, may result even in cancer (Haanen and 
Vermes 1996; Alberts et al. 2008).  
The cell undergoing apoptosis displays characteristic morphological changes. First, 
the cell shrinks and condensed chromatin collapses into crescents around the nuclear 
envelope. Then, the membrane begins to bulge and bleb. Finally, blebbing increases 
and the cell breaks into number of apoptotic bodies, which are phagocytosed in vivo 
and lysed in vitro (secondary necrosis) (Alberts et al. 2008) (Figure 6). 
Cell damage inducing factors such as heat, radiation, hypoxia, increased 
intracellular calcium and direct cell-to-cell contacts can trigger apoptosis. Among 
others two major apoptotic pathways have been widely studied, namely extrinsic and 
intrinsic. The first one requires activation of Fas receptor (FasR), also known as 
apoptosis antigen 1 or cluster of determination 95 (CD95), by Fas ligand (FasL), 
which is expressed by cytotoxic T-lymphocytes.  Activation of FasR triggers Fas 
associated death domain (FADD) binding, which facilitates activation of caspase-8 
and therefore starts a proteolytic apoptotic cascade. Tumor necrosis factor alpha 
(TNFα), a proinflammatory cytokine and immune cell regulator, activates TNF 
receptor 1 (TNFR1 or CD120) , that triggers TNFR1-associated death domain protein 
(TRADD) recruitment and subsequent activation of FADD as well. However, 





(Inazawa et al. 1992; Chen and Goeddel 2002; Wajant et al. 2003; Lee et al. 2012; 
Liu et al. 2012). 
The intrinsic (or mitochondrial) pathway is associated with Bcl-2 protein family 
members and increased permeability of the outer membrane of the mitochondrion and 
release of cytochrome C from the intermembrane space into the cytoplasm. Bcl-2 
family comprises both pro- (BAX, Bak, Puma Noxa, Bid etc.) and anti-apoptotic (Bcl-
2, Bcl-xL, Mcl-2 etc.) proteins. In non-apoptotic cells pro-apoptotic proteins are 
engaged with anti-apoptotic proteins and this balance secures the cell from apoptosis. 
Up-regulation of pro-apoptotic proteins via MAPK (JNK2, p38 etc) pathways shifts 
the balance and the cell undergoes apoptosis. BAX and Bak form an oligomeric pore, 
also known as mitochondrial apoptosis-induced channel (MAC) in the outer 
membrane of the mitochondrion. Released cytochrome C initiates formation of 
apoptosome, which in turn facilitates activation of caspase-9 and therefore starts the 
proteolytic apoptotic cascade (Kroemer et al. 2007). 
The crosstalk between extrinsic and intrinsic pathways exists in Fas-mediated 
apoptosis. Caspase-8 cleaves pro-apoptotic BH3 interacting-domain death agonist i.e. 
Bid into truncated tBid form. In turn, tBid engage anti-apoptotic Bcl-2 and Bcl-xL 
proteins, allowing disengaged Bak and BAX to translocate to the outer mitochondrial 
membrane and form MAC (Wei et al. 2000). 
Apoptosis is considered as a key event in SS pathogenesis. Salivary epithelial cells 
express immunoreactive molecules implicated in antigen presentation (MHC-I, II) and 
apoptosis (FasR). Activated epithelia also produce chemokines (CXCL13, CXCL21, 
BAFF) and cytokines (IL-1, IL-6, IL-8, TNF-α) contributing to creation of an 
inflammatory milieu and T- and B-lymphocyte infiltration. (Kong et al. 1997; Fox et 
al. 1999; Herrera-Esparza et al. 2008). The majority of infiltrating T-lymphocytes are 
CD4+ and their prevalence correlate with lesion severity with higher values at the 
intermediate stages of the disease, whereas prevalence of CD8+ autoreactive T-
lymphocytes remains constant. The percentage of NK-cells, macrophages and 
dendritic cells is small as compared to T-cells, but it also positively correlates with 
lesion severity. Abundance of danger/apoptosis-inducing signals in focal lymphocytic 
infiltrates results in intensified epithelial apoptosis and increased production of 
exosomes and apoptotic bodies, containing hidden nuclear “cryptic” SS-A/B-hY RNA 
ribonucleoproteins and other abnormally cleaved proteins (type 3 muscarinic 
acetylcholine receptor, α-fodrin etc.), identified as important autoantigens in SS. 
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Subsequently, immunogenic autoantigens are processed by APCs, that results in B-
cell driven autoimmune responses, i.e. production of autoantibodies (Nagaraju et al. 
2001; Trokovic et al. 2012; Kyriakidis et al. 2014). Taken together, these data suggest 
apoptotic salivary epithelia as an initiative component of SS pathogenesis. 
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5. AIMS OF THE STUDY 
 
Sjögren's syndrome is a chronic autoimmune diseases with unknown aetiology and 
multidirectional complicated pathogenesis. Taken together, over the last two decades 
continuosuly emerging data suggest salivary epithelium as a key player and conductor 
of autoimmune responses in the disease. Recently discovered histamine H4 receptor 
keeps drawing attention and interest regarding its implication on autoimmune 
processes. This novel receptor was found in the majority of human tissues, including 
immunocompetent cells and epithelium. Thus, there is a reason to believe that H4R-
mediated histamine signalling can contribute to etiopathogenesis of SS. To explore 
this theory the following objectives were tested: 
 
1. The profile of human salivary gland histamine receptors and in particular 
expression of functional H4R in the salivary epithelia of SS and healthy 
individuals. 
 
2. Expression of histamine transporters and metabolizing enzymes in the salivary 
glands of SS patients. 
 
3. The regulation of activated H4R on Fas-mediated apoptosis of the salivary 
epithelium. 
 
4. Some factors, which might explain down-regulation of H4R expression in salivary 
epithelium in Sjögren’s syndrome. 
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6. MATERIALS AND METHODS 
 
6.1. Patients and the samples (I, II, IV) 
 
 Study I Study II 
SS Healthy SS Healthy 
Number of salivary 










Age, mean ± SD 48,8±5,4 47,1±5,8 53,9±6,2 47,1±5,8 
Resting saliva flow, 
ml/15 min, 
mean ± SD 
0,5±0,4 0,9±0,3 0,6±0,4 0,9±0,3 
Focus score, 
mean ± SD 1,7 ± 0,3 <1 1,6±0,3 <1 
Number of fulfilled 
SS criteria* 6 out of 8 - 6-7 out of 8 - 
Fixation IF, PCR: snap-frozen IHC: formalin, paraffin-embedded 
* Reference: (Vitali et al. 2002) 
 
Snap-frozen murine salivary glands from 1-month-old BALB line (2 samples) and 
4-7-months-old NOD line (7 samples) were a generous gift from our colleagues from 
University of Turku, Finland. Snap-frozen murine salivary glands from 
orchidectomized (4 samples) and non-orchidectomized (4 samples) original 
HDC+/HDC+ genotype murine line, used for generation of HDC knock-out line 
(Ohtsu et al. 2001), were a generous gift from our colleagues from Semmelweis 
university of Budapest, Hungary. The ethics committee of the Hospital District of 
Helsinki and Uusimaa approved the study (19/E5/03) and all patients gave their 
informed consent. The study did not comprise any experiments on living animals. 
Murine samples were taken outside University of Helsinki according to approved by 








6.2. H4R agonists (I, III) 
Code Formula pKi  hH4R and Ki  hH4R, nM 




12 ± 3 28,4 





45 ± 16 85 
(Kottke et al. 
2011) 
* Functional binding assay with [35S]GTPγS on membrane preparation of Sf9 cells expressing 
hH4R, co-expressed with Gαi2 and Gβ1γ2 subunits. The values relate to maximal 100% response of 
histamine. 
 
6.3. HSG cell culture (I, II) 
The derevative from human HeLa cells (HSG), which are morphologically cervical 
cancer epithelial cells (earlier expected to represent human submandibular gland-
derived salivary gland ductal cell line), were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM)-Ham’s F-12 nutrient mixture supplemented with 2-2,5 mM 
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycine and 10% fetal bovine serum 
(FBS, HyClone). In the study I the HSG cells were stimulated with 10 μM H4R 
agonist ST-1006 for 24 hours in reduced 2% FBS medium with subsequent collection 
and storage at –80°C.  
 
6.4. NS-SV-AC acinar cell culture (III) 
Initially, the cells were cultured on human collagen-1 coated matrix plastic plates 
in K-SFM containing 100 U/ml penicillin and 100 μg/ml streptomycine, 
supplemented with 25 μg/ml BPE and 0,1-0,2 ng/ml rhEGF (Life Technologies) for 
24 hours. Collagen-1 and BPE were necessary for attachment of the cells to the plastic 
surface of the plates. Next day, the medium was changed to BPE-free K-SFM, 
because BPE is a source of ≈42,5 nM background histamine, which is enough to 
compete with H4R agonist HST-10 in further experiments. Background histamine 
concentration was measured with high performance liquid chromatography. 
Internalization and apoptosis experiments were performed 24 hours after the change 
of the medium. 
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6.5. Multiplex and ELISA assays (I) 
Multiplex kit (Cat No. HCYTOMAG-60K-PX39, Millipore) was used to screen 39 
cytokines, chemokines and other growth factors in the HSG cells medium after ST-
1006 stimulation. According to manufacturer’s instructions the standards and samples 
were pipetted in duplicates into 96-well plates and mixed with internally labelled 
polystyrine beads with different ratios of 2 spectrally distinct fluorophores and coated 
with anti-human cytokine capture antibodies for 1 hour. Later, the wells were washed 
3 times and phycoerythrin-conjugated secondary detector antibodies were added for 
45 min. Wells were washed twice, assay buffer was added, and samples were 
analyzed using a fluorescent bead–based flow cytometer equipped with 2 lasers (Bio-
Plex 200 System; Bio-Rad). 
As a result, two potential H4R-regulated proteins IL-8 and VEGF were selected for 
subsequent validation with ELISA test system (Quantikine; R&D Systems). The 
analysis was also performed according to manufacturer’s instructions. Pre-diluted in 
assay diluents samples and standards were added into 96-well plates for 2 hours and 
then washed 4 times with buffer. The plate surface was separately pre-coated with 
monoclonal antibodies against IL-8 and VEGF. Horseradish peroxidase–conjugated 
detector antibodies were added for 1–2 hours, followed by 3 washes and by addition 
of H2O2 substrate and tetramethylbenzidine chromogen solution for 20–30 minutes. 
Absorbance at 450 nm was measured within 30 minutes using Chameleon-V 
microplate reader (MicroWin 2000 Lite software; Hidex, Turku, Finland). 
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6.6. Used Primary antibodies  
1Department of Molecular Biology and Biochemistry – Unit 741 of CIBERER, University of 
Málaga, Málaga, Spain.  
2Department of Visceral, Transplant and Thoracic surgery, Molecular biology laboratory, Medical 
University of Innsbruck, Innsbruck, Austria (Schwelberger et al. 2013). 
3Dr Margarete Fischer-Bosch institute of Clinical Pharmacology and University of Tübingen, 
Stuttgart, Germany 
4Integrative Neuroscience, School of Biological and Biomedical Sciences, Durham University, 
Durham, United Kingdom. 
 





Study I (IHC) 
H4R 
Synthetic peptide, first cytoplasmic 
domain of human H4R 
Rabbit 
polyclonal 0,5 μg/ml MBL Int. 
Study II (IHC, IF) 





DAO 169-415 fragment of human DAO (HYB313-03) 
Mouse 
monoclonal 1:500 H. Schwelberger
2 
HNMT Synthetic peptide, N-terminal region of human HNMT 
Rabbit 
polyclonal 2,5 μg/ml Abcam 
OCT2 Synthetic peptide, C-terminal sequence of human OCT2 
Rabbit 
polyclonal 1:100 A. Nies
3 
OCT3 Synthetic peptide, C-terminal sequence of human OCT3 
Rabbit 
polyclonal 1:100 A. Nies
3 
SMA Synthetic peptide, N-terminal sequence of human SMA 
Goat 
polyclonal 5 μg/ml Everest biotech 
Study III (WB) 
cPARP p25 cleaved form of human PARP Rabbit monoclonal 3,8 ng/ml Abcam 
ERK1/2 Synthetic peptide corresponding to 336-356 fragment of human ERK1 
Mouse 
monoclonal 0,25 μg/ml Millipore 
pERK1/2 Phosphopeptide containing the pTEpY motif of human ERK1/2 
Mouse 
monoclonal 0,1 μg/ml Millipore 
JNK GST fusion protein corresponding to full-length rat SAPK1a 
Rabbit 
polyclonal 1 μg/ml Millipore 
pJNK Peptide corresponding to human pJNK at T183/Y185/T221/Y223 
Rabbit 
polyclonal 1 μg/ml Millipore 
Bcl-XL Synthetic peptide corresponding to 1-100 fragment of human Bcl-XL 
Rabbit 
monoclonal 0,128 μg/ml Abcam 
BAX Synthetic peptide corresponding to 1-100 fragment of human BAX 
Rabbit 
monoclonal 0,114 μg/ml Abcam 
Unpublished data (IHC, IF) 
H1R 
Synthetic peptide, second 
extracellular domain of human H1R 
Rabbit 
polyclonal 0,5 μg/ml MBL Int. 
H2R 
Synthetic peptide, third 
extracellular domain of human H2R 
Rabbit 
polyclonal 0,5 μg/ml MBL Int. 
H3R 
Synthetic peptide, third cytoplasmic 
domain of human H3R 
Rabbit 
polyclonal 0,5 μg/ml MBL Int. 
H4R 
Synthetic peptide corresponding to 
a fragment of human H4R 
Rabbit 
polyclonal 0,497 μg/ml P. Chazot
4 
moH4R 
Synthetic peptide corresponding to 
a fragment of mouse H4R 
Rabbit 
polyclonal 0,452 μg/ml P. Chazot
4 
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6.7. Immunohistochemical staining (I, II) 
4-μm sections of labial salivary glands (LSG) were deparaffinised and rehydrated. 
Antigen retrieval was performed in MicroMED T/T Mega microwave processing 
labstation for histology (Milestone) at 95°C for 15 min in 10mM sodium citrate 
buffer, pH=6, followed by cooling to a room temperature for 30 minutes. Later, the 
slides were washed in tap water and incubated in peroxidase-blocking solution (Dako) 
for 15 minutes, followed by 5 minutes wash in PBS. Epitope blocking was done by 
incubation in 10% normal goat/horse serum (Vector) for 1 hour at room temperature. 
Then, listed above primary antibodies were applied to the sections overnight at +4°C. 
Non-immune 0,5-2,5 μg/ml rabbit or mouse IgG were used for negative control 
staining. Next morning, the slides were washed in PBS 3 x 5 minutes, then incubated 
in appropriate biotin-conjugated secondary antibodies against certain primary IgG 
(1:200 in 1,25% BSA-PBS; Vector) for 1 hour, then incubated in avidin-biotin-
peroxidase complex (1:200 in water; Vector) for 45 minutes. Colour reaction was 
developed by 0,006% hydrogen peroxide and 0,023% 3,3´-diaminobenzidine 
tetrahydrochloride (DAB) or metal enhanced DAB for 5-7 minutes. The slides were 
counterstained in haematoxyline or fast-red, dehydrated, mounted and covered. The 
sections were photographed using a Leitz Diaplan microscope and a 5MP Leica 
DFC420 digital camera (Leica Microsystems). In study II, human kidney tissue 
sections were used as positive sample controls (DAO staining).   
 
6.8. Histamine transport studies (II) 
The study was performed by our co-workers in M. Fischer-Bosch Institute of 
Clinical Pharmacology, Stuttgart, DE and original protocol described in our co-
worker’s publication (Nies et al. 2011). 
The studies were performed as follows: Briefly, all cultures were incubated at 
+37°C. HSG cells (5x105/well) were seeded into 24-well cell culture plates and grown 
for 24 hours. Next day, the cells were washed with uptake buffer (130 mM NaCl, 25 
mM hydroxyethylpiperazine ethanesulfonic acid, 1.2 mM KH2PO4, 4.8 mM KCl, 1.2 
mM CaCl2, 1.2 mM MgSO4, 5.6 mM glucose, pH 7.4). Uptake was initiated by 
replacing this with uptake buffer supplemented with 100 nM [3H]histamine 
(dihydrochloride, 392 GBq/mM; PerkinElmer, Waltham, MA), without and with 2 
mM 1-methyl-4-phenylpyridinium (MPP), a model cation which inhibits organic 
cation transporters. Three washes in ice-cold uptake buffer stopped the uptake at 
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indicated time points, followed by lyses in 0.2% SDS. Intracellular radioactivity was 
determined by liquid scintillation counting (Hidex 300SL TDCR liquid scintillation 
counter, Turku, Finland). In some experiments, NaCl in the uptake buffer was 
replaced with 260 mM glucose. 
For efflux studies, cells were pre-incubated for 60 min in uptake buffer containing 
100 nM [3H]histamine and then washed 3 times with ice-cold uptake buffer. Efflux 
was initiated by addition of uptake buffer (without [3H]histamine). Radioactivity 
([3H]histamine) in the cell culture medium and cells was measured as above at the 
time points of 0.5 – 1 – 2 – 5 – 10 – 20 and 30 min. 
 
6.9. Immunofluorescence staining (II, IV) 
Snap-frozen 4 μm thick sections of LSG and murine salivary glands were 
incubated in 10% normal donkey serum for 1h at room temperature. Then, for 
histamine transport studies generously provided by our co-workers OCT2 (Nies et al. 
2008) and OCT3 (Nies et al. 2009) antisera combined with SMA antibodies, for 
murine and additional H4R studies generously provided by our co-workers in-house 
raised anti-mouse H4R antibodies (Lethbridge and Chazot 2010) and in-house raised 
anti-human H4R (van Rijn et al. 2006) were applied to the sections overnight at +4°C, 
followed by next morning 3 x 5 min PBS wash. After that, appropriate mixture of 
secondary antibodies (Do anti-Rb AlexaFluor 488-conjugated, Do anti-Go AlexaFluor 
568-conjugated, Go anti-Rb AlexaFluor 568-conjugated, dilution 1:200 in PBS) were 
applied to the sections for 1 hour at room temperature, followed by another 3 x 5 min 
PBS-wash. Nuclear counterstaining with DAPI was done for 5 min at room 
temperature, followed by 3 x 5 min wash in distilled water. The sections were 
mounted and photographed by Leica DM6000 microscope and DFC365FX digital 
camera (Leica Microsystems, DE). Immunogen-containing absorption controls 
confirmed specificity of OCT2 and OCT3 antisera. 
 
6.10. Immunofluorescence visualization of H4R internalization in NS-SV-AC 
cells (III) 
The cells were seeded on glass coverslips into plastic 24-well plate (1x105 
cells/well) and cultured as previously described in section 6.4. Later, the cells were 
once gently washed with pre-heated 37°C PBS, followed by gentle change to 100 nM 
HST-10-containg K-SFM without BPE. Parallel cell sets were pre-treated with 10 
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mg/ml MβCD (Sigma, DE) for 1 hour prior to HST-10 stimulation. The cells we fixed 
in -20°C absolute methanol for 10 minutes after 5, 30, 60 and 180 minutes HST-10 
stimulation, followed by 3 x 5 min wash in PBS. Fixed cells were incubated in 10% 
donkey normal serum for 1 hour at room temperature. After that H4R antibodies were 
applied to the cells for overnight at +4°C, followed by 3 x 5 min wash in PBS. 
Secondary Do anti-Rb AlexaFluor 488-conjugated antibodies were applied for 1 hour 
at room temperature, also followed by 3 x 5 min PBS wash. Nuclear counterstaining 
with DAPI was done for 5 min at room temperature, followed by 3 x 5 min wash in 
distilled water. The coverslips were mounted, visualized by Leica DM6000 
microscope and photographed by DFC365FX digital camera. Negative control (0,5 
μg/ml non-immune Rb IgG, R&D systems, MN) confirmed specificity of the primary 
antibodies. 
 
6.11. Apoptosis induction (III) 
Initial seeding density of NS-SV-AC cells was 3,5x105 per well in 6-well plates. 
The cells were stimulated 8 hours prior induction of apoptosis with 5, 25, 50 and 100 
nM HST-10 diluted in K-SFM, which didn’t contain BPE. Apoptosis was induced by 
100 ng/ml rhTNFα and 125 nM NF-κB inhibitor IMD-0354. The last one was 
required to sensitize the cells to TNFα-induced cell death. 100 nM staurosporine 
(Merk, DE) was used to induce positive control apoptosis for Western Blot 
experiments. 
 
6.12. Phase contrast microscopy and Flow cytometry (III) 
The apoptosis of NS-SV-AC cells at the time point of 36 hours was observed and 
analysed using Leica DM6000 microscope and photographed by DEC420 colour 
camera. 
After that, the cells were collected and labelled with Alexa Fluor 488 Annexin V 
and propidium iodide from Dead Cell apoptosis kit for flow cytometry, according to 
manufacturer’s instructions (Invitrogen, UK). Fluorescence emission at 530 nm and 
575 nm was measured by BD Accuri C6 flow cytometer (BD Bioscience). Each 





6.13. Western Blotting (III) 
Apoptotic and control NS-SV-AC cells were collected at the time points of 2,5-5-
15-30-60 and 150 minutes for analysis of MAPKs and at the time point of 36 hours 
for analysis of cPARP, Bcl-XL and BAX. After pelleted by centrifugation at 1500 g 
cells were lysed by cell lysis buffer (Cell Signalling, MA) for 15 minutes on ice with 
agitation, then briefly sonicated and centrifuged at 14.000 g, +4°C for 10 min. 
Supernatant was collected and total protein concentration was measured using Pierce 
BCA Protein Assay Kit (Thermo Scientific, IL). The lysis buffer contained 0,1% 
SDS, protease inhibitors (Roche, DE) and phosphatase inhibitors (Thermo Scientific, 
IL). 
SDS polyacrylamide gel electrophoresis was performed according to a 
modification of the method by Laemmli, using 1,5 mm TGX Stain-Free Fast Cast 
10% polyacrylamide slab gel (Bio-Rad, CA). Total protein amount of the samples was 
adjusted to 9-22 μg/lane, depending on efficiency of binding affinity of the primary 
antibodies. Running sample mixture was comprised of sample in 6X Red Loading 
Buffer and 30X DDT (New England BioLabs Inc, MA). The proteins in the sample 
mixture were denatured at +95°C for 10 minutes and plied to the gels, followed by 
electrophoresis and blotting to PVDF membranes. Then the membranes were washed 
in TBS for 10 minutes. Non-specific epitopes were blocked by 3% BSA blocking 
buffer for 1 hour at room temperature. Membranes were incubated in the above-listed 
primary antibodies at +4°C overnight either in PBS ± 0.1% Tween-20 or TTBS ± 5% 
milk / 2% BSA. Next morning the membranes were washed 3x10 minutes in TTBS 
and appropriate goat anti-rabbit/mouse HRP-conjugated secondary antibodies were 
applied for 1 hour at room temperature. The membranes were again washed 4x10 
minutes in TTBS and HPR binding sites were detected by chemiluminescent reaction 
using Bio-rad Immun-Star WesternC Kit and Bio-rad ChemiDoc MP Imaging system. 
Intensity of the bands was normalized to stain-free total protein loading controls and 
analysed by Bio-rad Image Lab software. 
 
6.14. Quantitative Real-time PCR (I, II, III, IV) 
Salivary gland total RNA was isolated from frozen samples using a High Pure 
RNA Tissue kit (Roche, CH). Apoptotic and control NS-SV-AC cells were pelleted at 
14.000 g at +4°C for 10 min at the time point of 20 hours after initiation of apoptosis. 
Total RNA from NS-SV-AC cells was isolated using RNeasy Plus Mini kit (Qiagen, 
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DE). Complementary DNA (cDNA) was synthesized using SuperScript First Strand 
cDNA synthesis kit (Invitrogen, CA).  
Total HSG cell RNA was extracted using the MirVana miRNA isolation kit 
(Ambion, US). cDNA was synthesized using the High Capacity cDNA Reverse 
Transcription kit (LifeTech, MA). 
For human H4R, HDC, DAO, HNMT, housekeeping human β-actin, housekeeping 
human GAPDH and housekeeping murine β-actin gene transcripts, quantitative RT-
PCR was performed using the iCycler iQ5 Multicolor Real-Time PCR Detection 
System and iQ SYBR Green Supermix Kit (Bio-rad). Sequences of primers are listed 
in the table below. Expression levels of human OCT1, OCT2, OCT3 and PMAT 
mRNAs were quantified by TaqMan technology on 7900HT RT-PCR system 
(LifeTech). Expression levels of murine H4R mRNA were quantified by TaqMan 
technology on iCycler iQ5 Multicolor Real-Time PCR Detection System and FAM-
labelled iTaq DNA polymerase kit (Bio-rad). 
 
Primers used in qRT-PCR experiments 
Name Sequences of the primers Study 
H4R 
Forward: 5’-TGG AAG CGT GAT CAT CTC AG-3’ 
Reverse: 5’-ATA TGG AGC CCA GCA AAC AG-3’ I 
HDC Forward: 5’-TTG ATT GCC CTG CTG GCA GC-3’ Reverse: 5’-TGC ACA GAC AAA GAC GGG CAC C-3’ II 
HNMT Forward: 5’-TGG CAT CTT CCA TGA GGA GCT T-3’ Reverse: 5’-AAA ATC CCA AAG CAG GTC TCC AT-3’ II 
DAO Forward: 5’-GCT ACG TCC ACG CCA CCT TCT A-3’ Reverse: 5’-CCC AGG CCA CCA GGT CCT CA-3’ II 
Bcl-xL Forward: 5’-GAT CCC CAT GGC AGC AGT AAA GCA AG-3’ Reverse: 5’-CCC CAT CCC GGA AGA GTT CAT TCA CT-3’ III 
BAX Forward: 5’-CGG GTT GTC GCC CTT TTC TA-3’ Reverse: 5’-GTC CAA TGT CCA GCC CAT GA-3’ III 
β-actin Forward: 5’-TCA CCC ACA CTG TGC CCA TCT ACG A-3’ Reverse: 5’-CAG CGG AAC CGC TCA TTG CCA ATG G-3’ I, II 
GAPDH Forward: 5’-AAG GTC ATC CCT GAG CTG AA-3’ Reverse: 5’-TGC TGT AGC CAA ATT CGT TG-3’ III 
OCT1 Forward: 5’-CAT CAT AAT CAT GTG TGT TGG CC -3’ Reverse: 5’-CCC TTG GTC TCT GGA AGA AGT AG-3’ II 
mouse 
β-actin 
Forward: 5’-CTT CTT TGC AGC TCC TTC GT -3’ 





6.15. Statistical analysis (I, II, III, IV) 
Quantified data are presented as mean ± SEM. Online two-tailed Mann-Whitney U 
test was used for comparisons and significance (skewed qRT-PCR data in the studies 
I, II, IV). Online one-way ANOVA or MS Excel Student’s t-test were used to 
estimate statistical significance of differences between groups with normally 
distributed data (ELISA results in the study I; Flow cytometry data, Western Blot data 




7. RESULTS AND DISCUSSION 
 
7.1. Histamine receptors profile in the salivary glands 
At the very beginning of the project, we hypothesized, that H4R might be 
expressed in the salivary glands of healthy human individuals and somehow 
contributes to pathogenesis of SS. Additionally, in order to determine possible 
histamine-mediated effects in the human salivary glands in SS, the convectional H1R, 
H2R as well as H3R were also studied. Immunohistochemistry clearly revealed the H-





A. IHC staining of H-receptors 
in the salivary glands from 
healthy individuals and SS 
patients. 
In healthy salivary glands H1R 
was localized only in the 
endothelial cells of the blood 
vessels. H2R was not detected 
by IHC. H3R was localized in 
the myoepithelial cells around 
the acini and ducts. H4R 
localized in the acinar and in 
ductal epithelial cells. IHC 
revealed no difference in 
expression of H1R and H2R in 
SS samples as compared to 
healthy samples. Both H3R and 
H4R were stained weaker in SS 
samples as compared to 
samples of healthy salivary 
glands.  
 
B. IF staining of H4R using 
antibodies provided by prof. P. 
Chazot. Membrane staining of 
H4R can be observed in 
healthy acini, whereas acini in 
SS are H4R-negative. 
Bars = 50 μm   
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According to the results of immunohistochemical staining, localization of H1R in 
both healthy and SS biopsies was restricted to blood vessel endothelium and solitary 
lymphocytes of inflammatory foci in SS samples. This finding is in line with studies 
of others and dogma of H1R-mediated vascular dilatation and permeability (Van de 
Voorde and Leusen 1983; Li et al. 2003). However, the observed results were 
contradictory to those of Kim J-H. et al., who showed H1R expression “distributed 
across most of the human submandibular gland including acinar and ducts” (Kim et 
al. 2009), which might result from cross-reactivity or false-positive staining. H2R 
protein was not immunohistochemically detected neither in healthy salivary biopsies, 
nor in biopsies from SS patients. 
The most intriguing results of IHC staining were observed regarding H3R and H4R. 
In healthy salivary glands localization of H3R corresponded to myoepithelial cells 
around the acini and the ducts. H4R was localized in the acinar cells and in the goblet 
cells of the ducts. Immunoreactivity of both H3R and H4R was lower in most of SS 
samples as compared to healthy samples. Results of qRT-PCR seemed in line with 
those of IHC, since expression of H4R were relatively low in SS samples compared to 
healthy samples at mRNA level, but the difference did not reach statistical 
significance. Positive myoepithelial staining pattern of H3R may be a result of 
expression of the receptor on the surface of myoepithelial cells and/or due to 
expression on the surface of cholinergic fibres, which innervate myoepithelial cells. 
This finding is in accordance with those of investigators, who showed that regardless 
of the predominant localization in the central nervous system, H3R is also expressed 
in the peripheral nerve fibres inhibiting local cholinergic transmission (Ichinose and 
Barnes 1989; Cannon et al. 2007). H3R localization is also demonstrated in a number 
of muscular cells, such as bronchial smooth muscle cells (Cardell and Edvinsson 
1994), bladder detrusor cells (Neuhaus et al. 2006) and even in the skeletal myotubes 
(Chen et al. 2015). The impact of H3R in salivary gland maintenance and 
pathogenesis of SS is still an open question and interesting approach for future 
studies.  
H4R immunohistochemical reactivity was localized in the acini and in the goblet 
cells of the ductal epithelium in healthy LSG. H4R immunoreactivity in most of SS 
LSG samples was visibly lower, compared to healthy samples (Figure 7, A). Use of 
second in-house raised antibodies against human H4R (a generous gift from prof. P. 
Chazot) revealed clear membrane localization of H4R in IF staining (Figure 7, B). 
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These findings encouraged us to continue studies towards finding the role of 
histamine/H4R in SS. 
Murine NOD lines are often used as animal models for SS studies. Salivary glands 
of NOD mice are characterized by similar lymphocytic infiltrates to those observed in 
SS (Braley-Mullen and Yu 2015). Parallel immunofluorescence studies revealed clear 
presence of moH4R in the murine salivary glands. Interestingly, moH4R was present 
exclusively on the surface of the apical membrane of acinar and ductal epithelia as 
compared to human samples, where an all-over membrane localization of the receptor 
was observed (Figure 8). Unfortunately, there was no significant difference of the 
moH4R expression pattern in the salivary glands of the SS model NOD line compared 
to the healthy control BALB line. Thus, most of further studies were performed using 
biological materials from human species. 
  
Figure 8. Immunofluorescence staining of moH4R in murine salivary glands. The receptor (red colour) 
was localized with sharp apical staining pattern in the acinar (star-like patterns) and ductal epithelial cells 
of the gland. A = Negative control (1-month-old BALB line). B = control 1-month-old BALB line. 
C = 4-months-old NOD line. D = 7-month-old NOD line. Bar ≈50 μm 
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7.2. Histamine transport and metabolism in the salivary glands (II) 
 
7.2.1. Histamine metabolizing enzymes in LSG 
Exclusive histamine synthesizing enzyme HDC and intracellular histamine 
degrading enzyme HNMT were found in the healthy LSG. Immunoreactivity of those 
enzymes was found in the ductal epithelium, predominantly in the intralobular 
excretory salivary ducts of both healthy and SS LSG without significant difference in 
protein expression pattern. Extracellular histamine degrading enzyme DAO was not 
found in either of groups of samples. These results were completely supported by 
qRT-PCR. 
Based on the mentioned above results of IHC and qRT-PCR, it is reasonable to 
propose, that local synthesis and degradation of histamine in the salivary glands are 
not altered in SS patients. 
 
7.2.2. Histamine transporters in LSG 
mRNA levels of major histamine transporters OCTs and PMAT were measured in 
the salivary glands of healthy- and SS individuals. OCT3 mRNA was present at levels 
over 100-fold higher than the rest of tested transporters. Healthy LSG samples 
showed significantly higher expression of OCT3 as compared to SS samples 
(p=0.028). This result supports OCT3 as a major histamine transporter in salivary 
glands. Later, IF staining showed strong basolateral membrane localization of OCT3 
in the epithelial cells of healthy LSG (Figure 9). SS samples were almost OCT3-
negative in IF staining, supporting results of qRT-PCR. These results suggest, that 
transport of histamine via OCT3 is altered in the acinar and ductal epithelia in SS.  
Double IF staining revealed co-localization of OCT2 and smooth muscle α-actin in 
the myoepithelial cells of salivary glands from healthy individuals. SS samples 
showed much weaker expression of OCT2, as compared to healthy samples.  
Figure 9. 
Representative IF figures 
of OCT3 in the salivary 
glands 6 healthy controls 
and 8 SS patients with 
similar results. 
Bar = 50  
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7.2.3. Histamine transporters in HSG cells 
In qRT-PCR experiments, HSG cells expressed OCT3 mRNA at a level of over 
10-fold higher than OCT1 and OCT2, and over 2-fold higher than ENT4/PMAT, 
supporting a leading role for OCT3 in histamine transport in HSG cells. Preloaded 
HSG cells were able to release [3H]histamine into histamine-free medium in a time-
dependent manner. Conversely, HSG cells showed also time-dependent [3H]histamine 
uptake from the loading buffer, but not in the presence of OCT3 inhibitor MPP. 
 
7.2.4. OCT3 in murine salivary glands 
Immunofluorescence staining revealed OCT3 in the murine salivary glands. Three 
types of glands were stained: submandibular, parotid and sublingual. OCT3 was 
observed in the acinar and ductal epithelia in submaxillary and sublingual salivary 
glands. The staining signal was restricted to the apical membranes of the cells of the 
salivon, appearing as a star-like staining pattern. Additionally, OCT3 strong 
immunoreactivity was observed in the round-shaped structures, which could be 
identified as blood vessels and also in the solitary spindle-like cells in stroma of the 
glands, which could be mast cells and/or dendritic cells. Immunoreactivity of OCT3 
in the parotid gland was mostly observed in the apical membrane of ductal cells, 
whereas acinar staining was weak, as compared to sublingual and submandibular 
glands (Figure 10).  
Submaxillary gland in mice is homologous to human submandibular gland, and is 
considered a mixed gland, because it contains both serous and mucous acini. 
Together, mainly mucus sublingual gland and submaxillary gland are major sources 
of the watery compound of total saliva. Thus, staining data suggest that in the salivary 
Figure 10. Double immunofluorescence staining of different salivary glands of 7-month-old NOD mouse. 
Green color corresponds to OCT3, red color corresponds to smooth muscle α-actin, blue color corresponds 
to nuclei (DAPI).  OCT3 was expressed in the apical membrane of the acinar (star-like staining pattern) and 
ductal epithelia (arrows), as well as in the blood vessels and the cells of stroma, presumably in the mast cells 
and/or dendritic cells (arrowheads). Bar ≈ 50 μm.  
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glands of NOD mice OCT3 is restricted to mucous-synthesizing epithelial cells, rather 
than to protein-rich serous protein-synthesizing cells. Apical membrane star-like 
staining pattern of OCT3 refers to co-localization with H4R in mice as well. Studies 
show, that apical membrane of the murine mucous salivary epithelium is equipped 
with water channel protein aquaporin-5 (AQP-5). The saliva secretion in AQP-5 
knock-out mice decreases significantly (Ma et al. 1999). Taking into account 
restricted apical membrane co-localization of H4R/OCT3/AQP-5, it can be speculated 
that H4R/OCT3-mediated effects of low-concentration histamine may play role in 
secretion of water into saliva via AQP-5 in mice. 
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Figure 11. Different conditions of the salivary gland epithelium 
A: Healthy salivary gland at resting “off-state”. Salivary epithelium continuously synthesizes and releases 
histamine  via OCT3. H4R is activated. 
B: Healthy salivary gland at active “on-state”. Epithelial cells uptake excessive amounts of histamine from the 
mast cells for degradation and secretion into the lumen.  
C: Salivary gland in Sjögren’s syndrome. Salivary epithelium is H4R and OCT3-negative. Mast cells release 
histamine, which is not uptaken by epithelial cells and promote H1R-mediated pro-inflammatory effects. 




7.3. Non-professional histamine producing cells and on/off-state conception in SS 
 
Professional histamine producing cells, such as mast cells, basophils and ECL-cells 
of the gastric mucosa utilize 53-kDa HDC with high enzymatic activity to synthesize 
histamine rapidly into the storage granules, from which it is released in a burst-like 
manner in order to reach momentary high local histamine micromolar concentrations 
(Ichikawa et al. 2010). These concentrations are enough to activate conventional H1R 
and H2R. Vast quantities of rapidly released histamine and subsequent H1R/H2R-
mediated effects are responses to alteration of a tissue, as they take part in various 
pathophysiological processes like allergy, acute inflammation, infection etc. This “on-
state” response is rapid, short-term and required to eliminate etiological factors. In 
turn, non-professional histamine producing cells, such as epithelial cells, utilize 
immature 74-kDa isoform of HDC with low enzymatic activity, continuously 
synthesizing and passively releasing histamine in low nanomolar concentrations into 
the extracellular space. These concentrations are enough to activate high affinity H3R 
and H4R. We believe that “off-state” long-term H3R/H4R-meditated effects are 
required to maintain local homeostasis and physiological responses. Based on our 
results we suggest, that in healthy salivary gland tissues histamine-mediated effects of 
professional and non-professional histamine producing cells are in balance in a way 
that epithelial cells serve as “histamine sinks”, which harbour unnecessary excessive 
histamine via OCT3, degrade it by HNMT and/or lead it out into the salivary lumen. 
Our studies showed that salivary glands are practically DAO-free, that makes 
extracellular histamine degradation rather unlikely. Thus, the epithelial 
OCT3/HNMT-mediated intracellular mechanism brings back homeostatic histamine 
quantity to the milieu (Figure 11, B). The studies show that number of histamine-
containing mast cells positively correlates with the degree of local immune 
inflammation as assessed by focus score counting in SS (Konttinen et al. 1990). 
Apparently, local inflammatory surroundings drive mast cells to release histamine 
into the milieu, therefore contributing to pathogenesis of the disease as is shown, for 
example, in oral lichen planus (Salem et al. 2015). Salivary glands of SS patients are 
H1R-positive. Activation of H1R increases cytosolic calcium, which may result in 
activation of endothelial eNOS and production of NO. This leads to vasodilatation 
and increased vasopermeability, helping to recruit more immunocompetent cells from 
the blood stream into lymphatic foci in the diseased salivary gland. A new suggested 
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role for the OCT3-positive salivary epithelial cells in the intracellular degradation of 
histamine is that they are down-regulated in SS. This can contribute to prolonged “on-
state” H1R-mediated pro-inflammatory effects (Figure 11, C). In vitro histamine 
transport studies in HSG cells supported this conclusion. Together with 
immunostaining results and qRT-PCR results, inhibition of [3H]histamine uptake in 
presence of MPP suggests a meaningful role of OCT3 histamine uptake in human 
salivary glands. 
It was very exiting to discover co-localization of OCT3/H4R and OCT2/H3R as a 
cell-type-specific compartmentalization within one functional unit of the gland. 
Especially, when OCT3/H4R co-localization was also observed in salivary glands 
from NOD mice. It may be assumed that histamine participates/regulates contractile 
function of the myoepithelial cells via co-localized OCT2 and H3R. At the same time, 
acinar, ductal and myoepithelial cells can uptake histamine via OCT2/3 for 
intracellular degradation, intracellular sequestration and/or salivary secretion. 
Histamine concentration in saliva is 0.31-12,4 ng/ml (2.8-112.7 nM) (Kejr et al. 
2010), which is exactly enough to activate high affinity H3R and H4R (Ki H3R = 15,8 
nM, Ki H4R = 7,9 nM) (Thurmond et al. 2008). In SS the basal maintenance of the 
resting “off-state” status seems to be disturbed due to reduced OCT3 and H4R 
expression in the acinar and ductal epithelial cells. Thus, observed deficiency of 
OCT2 and H3R can also contribute to SS pathogenesis as well, for instance, by 
impaired regulation of salivary flow. 
Many cells of the lymphocyte infiltrates in SS are H4R-positive non-professional 
histamine-producing cells. Among those are antigen-presenting dendritic cells, T- and 
B-lymphocytes (Zampeli and Tiligada 2009). Therefore, deranged histamine transport 
and degradation in salivary glands may also have effects on local immune reactions 
and lymphocyte infiltration in SS.  
 
7.4. H4R in the salivary gland cell cultures 
 
7.4.1. H4R regulates production of IL-8 and VEGF in HSG cells 
xMAP Multiplex screening with subsequent ELISA validation showed, that HSG 
cells are able to secrete IL-8 and VEGF. Accumulation of both cytokines was time-
dependent. 10 μM ST-1006-stimulated HSG cells secreted IL-8 and VEGF at higher 
concentrations compared to non-stimulated controls (Table 4). 
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Table 4. Accumulation of IL-8 and VEGF in the supernatant of ST-1006-stimulated 

















4 0,7±0,3 0,6±0,2 1,9±0,2 1,6±0,4 
8 0,8±0,4 1,5±0,3 1,9±0,3 2,1±0,3 
12 0,9±0,3 1,8±0,2* 2,2±0,2 2,6±0,5 
16 1,0±0,2 1,5±0,4 2,8±0,4 3,3±0,2 
24 1,2±0,3 1,6±0,4 3,3±0,3 4,5±0,3* 
32 1,4±0,2 2,0±0,3* 3,8±0,4 4,8±0,2* 
48 2,0±0,4 3,2±0,5* 4,2±0,4 7,0±0,4* 
* = p<0.05 in comparison to non-stimulated control. 
 
In this study we used 10 μM H4R specific agonist ST-1006 (Emax = 28,4 %) to 
stimulate HSG cells. Such concentration is about 1000-fold higher than dissociation 
constant of ST-1006 (Ki hH4R = 12 ± 3 nM) (Sander et al. 2009), what mimics 
micromolar histamine concentrations released from the activated mast cells into the 
milieu in the salivary glands of SS patients. Similar to SS, mast cell accumulation and 
degranulation was also demonstrated by Salem and co-workers in oral lichen planus, 
an autoimmune disorder characterized by oral mucosa lesions. It was also shown, that 
H4R was significantly down-regulated at mRNA level after 24 h exposure to 50 μM 
histamine and 10 ng/ml IFN-γ in squamous cell carcinoma cell line (Salem et al. 
2015). Based on this it can be speculated, that in SS patients H4R might also be down-
regulated influenced by an inflammatory milieu and by an excessively saturated  mast 
cell-derived histamine load. As a result, H4R-mediated local homeostatic maintenance 
of the desensitized epithelial cells is imbalanced. As a consequence, this may trigger 
an increased production of harmful cytokines. 
Results of this study support those of Lee et al., who demonstrated by use of 
Multiplex assay, increased levels of IL-8 in saliva in patients with primary SS (Lee et 
al. 2010) as well as in serum of patients with secondary SS (Eriksson et al. 2004; 
Hwang et al. 2014), but not in plasma (Szodoray et al. 2004). IL-8 (CXCL8) is a 
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chemotactic factor, which attracts neutrophils and other granulocytes towards the site 
of infection (Rossi and Zlotnik 2000).  
IL-8 is also known as a promoter of angiogenesis and together with VEGF 
theoretically can cause neovascularization of the salivary glands. Increased blood 
flow in the salivary glands of some SS patients has been reported (Steiner et al. 1994; 
Chikui et al. 2000) and more recently pro-angiogenic factors were studied (Szodoray 
et al. 2004; Delaleu et al. 2008; Sisto et al. 2012). However, the analysis of vascular 
organization of SS salivary glands for signs of angiogenesis resulted in controversial 
results between two research groups. By IHC sole staining of platelet endothelial cell 
adhesion molecule-1 (PECAM-1/CD31), hematopoietic progenitor cell antigen CD34, 
macrophages and histiocytes Sisto et al. showed increased neovascularization in 
association with the grade of inflammatory lesions in SS minor salivary glands (Sisto 
et al. 2014). In contrast, McCall et al. in immunofluorescence double staining of 
PECAM-1 and von Willebrand Factor demonstrated unchanged organization of blood 
vessels in SS, supported by unchanged levels of VEGF in SS salivary glands vs. 
controls in western blot experiments (McCall and Baker 2015). Both groups used the 
same standard histological focus score grading analysis of the specimens. Therefore, 
there is no solid agreement today on the role of VEGF in SS and this issue is still a 
matter of studies and debates. 
 
7.4.2. Internalization of H4R in NS-SV-AC cells 
NS-SV-AC cell line derives from isolated human salivary gland acinar epithelial 
cells (Azuma et al. 1993). This cell line exhibits acinar phenotype, which makes it 
more advantageous, compared to ductal phenotype HSG cells, which turn into acinar 
ones only upon culturing on matrigel. The purpose of this study was to check whether 
NS-SV-AC line express functional H4R. At the same time another more effective 
specific H4R agonist HST-10 (Emax = 85 %) became available to our disposal, and it 
was therefore used in the stimulation experiments. Internalization was detected by 
immunofluorescence staining and followed at several time points. Non-stimulated 
cells were weakly stained for H4R. 100 nM HST-10-stimulated cells exhibited major 
staining patterns of the receptor’s internalization phases: membrane (5 min), 
cytoplasmic/perinuclear (30 min), sequestration/disappearance of the signal (60 min), 
and recycling/reappearance of the signal (180 min). MβCD-pretreated cells exhibited 
delay in the internalization phases, showing that cytoplasmic staining still prevailed at 
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60 min and sequestration at 180 min (III, Fig. 1). Thus, we demonstrated that NS-SV-
AC cells express H4R, which was confirmed to be functional (as will be presented in 
paragraph 7.4.4 below), and MβCD inhibited clathrin-dependent internalization of 
H4R. Weak staining of non-stimulated cells and disappearance of receptor labelling at 
the sequestration phase was probably due to ability of the antibodies to recognize 3D-
conformational structure of the epitope in the 1st cytoplasmic domain of the receptor 
only in its ligand-coupled active state. 
 
7.4.3. NS-SV-AC cells undergo TNFα/IMD-0354-induced apoptosis 
To study if immortalized NS-SV-AC cells can undergo apoptosis, a combination of 
human recombinant TNFα with NF-κB inhibitor IMD-0354 as an apoptotic trigger 
was tested. The sole use of TNFα did not cause strong enough apoptosis even at 
concentration of 1 μg/ml. On the other hand, high micromolar concentrations of IMD-
0354 were able to induce rapid apoptosis, but not via the extrinsic pathway, which is 
considered important in terms of SS pathogenesis. Pilot experiments determined the 
best synergistically effective apoptosis-inducing doses as being 100 ng/ml TNFα and 
125 nM IMD0354, which were significantly ineffective in the sole experiments. 
Phase contrast microscopy showed typical apoptotic morphology of TNFα/IMD-
0354-stimulated NS-SV-AC cells, characterized by retraction of the cells, formation 
of apoptotic bodies and detachment from the surface. Control non-apoptotic healthy 
cells exhibited spindle-like shape without signs of structural changes/alterations in the 
cell membrane (Figure 12).  
Flow-cytometry experiments showed increasedAnnexin V and PI double labeling 
of TNFα/IMD-0354-stimulated NS-SV-AC cells, taken as signs of apoptosis and  
Figure 12. Phase contrast microscopy. Arrows point on live spindle-shaped NS-SV-AC cells in 
the presents of apoptosis-inducing TNFα/IMD-0354 mixture and 100 nM H4R agonist HST-10. 
Bar = 50μm.  
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secondary necrosis. Prevalence of apoptotic cells in the experimental medium was 
also observed as changes in distribution of the cell population on the scatter SSC/FSC 
plot (Figure 13). Finally, TNFα/IMD-0354-induced apoptosis was confirmed by 
increased late phase apoptosis marker cPARP in Western blot experiments, as a result 
of caspase proteolytic cascade. Use of staurosporine as positive control confirmed 
apoptosis in immunoblots (III, Fig. 2c). Thus, suitable TNFα-mediated apoptotic 
model for NS-SV-AC cells was developed and used in subsequent experiments.  
 
  
Figure 13. Fist row: apoptotic cells detected by flow cytometry using Annexin V and propidium 
iodide double staining. Second row: gated cell population in forward scatter (FSC) vs. side 
scatter (SSC) plot.  
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7.4.4. Anti-apoptotic activity of H4R in NS-SV-AC cells 
Activation of H4R by specific agonist HST-10 resulted in inhibition of 
TNFα/IMD0354-induced apoptosis of NS-SV-AC cells. Flow cytometry results 
showed decreased Annexin V and PI labeling of the apoptotic cells in the presence of 
HST-10 in the cell culture medium in a dose-dependent manner (Table 5). 
Statistically significant anti-apoptotic activity of HST-10 was reached at 
concentration of 100 nM. This dose was defined as the best effective dose and was 
used in all subsequent experiments.  Percentage of the live cells in 100 nM HST-10-
containing experimental medium was significantly higher as compared to non-
stimulated apoptotic control: 63±6% vs. 11±7% (p=0.003). On the other hand, the 
percentage of apoptotic (Annexin-V-labeled) cells was significantly lower in 100 nM 
HST-10-containing experimental medium, as compared to non-stimulated apoptotic 
control cells: 25±6% vs. 66±13% (p=0.022), respectively (Table 5). Phase contrast 
microscopy visually disclosed increased numbers of preserved spindle-like shaped 
non-apoptotic NS-SV-AC cells in HST-10-containing medium after induction of 
apoptosis (Figure 12, arrows). Finally, the H4R-mediated anti-apoptotic effect was 
confirmed in Western blot experiments that showed significantly decreased cleavage 
of PARP in HST-10-pretreated apoptotic cells (III, Fig. 2c). 
Further experiments were performed to study which intracellular MAPK pathways 
might provide protection against TNFα/IMD0354-induced apoptosis upon H4R 
activation. JNK and ERK MAPKs were analyzed using Western blot. 
TNFα/IMD0354-induced phosphorylation of both JNK and ERK in control NS-SV-
AC cells was clearly observed at 2.5 min, followed by drop to initial levels after 30 
min. HST-10 pretreatment caused inhibition of TNFα/IMD0354-induced JNK 
Table 5. Percentage of the live and apoptotic cells in flow cytometry experiments. 




















Live, % 78±3 11±7* 26±11 36±12 48±10 63±6** 
Apoptotic, 
% 17±3 66±13* 52±14 42±14 30±13 25±6** 





phosphorylation at 2.5 and 15 min, followed by rise to initial levels at 30 min (Figure 
14). HST-10 treatment did not cause significant effect on ERK phosphorylation. 
Elevated levels of pJNK and pERK at 60 min and 150 min were interpreted as 
reflection of secondary changes in the MAPK signaling pathways, rather than H4R-
mediated. 
Additionally, major members of Bcl-2 regulatory protein family were studied as 
markers of mitochondrial link of apoptosis. Pro-apoptotic protein BAX and anti-
apoptotic protein Bcl-XL were studied in TNFα/IMD0354-induced apoptosis in NS-
SV-AC cells at mRNA and at protein levels. Influence of apoptotic TNFα/IMD0354 
mixture upon the cells resulted in diminished levels of both BAX and Bcl-XL proteins 
at mRNA level after 20 h and at protein level after 36 h of treatment. H4R activation 
with HST-10 resulted in statistically significant up-regulation of anti-apoptotic Bcl-
XL at mRNA and protein level in TNFa/IMD0354-treated cell, while levels of BAX 
remained unchanged (III, Figure 4). Interestingly, active form ≈22 kDa BAX was not 
detected in Western blot experiments, probably due to Simian-virus-40-mediated 
suppression of BAX activation promoter p53 (Chipuk et al. 2004; Alwin Prem Anand 
et al. 2012; Lee et al. 2014). Instead, protein levels of BAX were analyzed based on 
inactive form of the protein (III, Figure 4e), which is suggested to be a dimer or small 
protein-coupled complex (Vogel et al. 2012). Presented data at least partly explains 
underlying molecular mechanisms of H4R-mediated protective effects of histamine 




Figure 14.  
Phosphorylation of JNK MAPK 
in TNFα/IMD0354-stimulated 
NS-SV-AC cells. Quantification 
of Western blots. 
Presented as mean ± SEM of 3 
independent experiments. 
R = reference mean.  
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7.4.5. Role of H4R in Sjögren’s syndrome  
Glandular epithelial cells are proposed to be a potent component in disease 
pathogenesis. Lymphocytic foci in the salivary glands in SS patients form and 
gradually enlarge around epithelial structures. The inherent abilities for intrinsic 
immunoreactivity of the salivary gland epithelium are supported by the presence of 
numerous molecules involved in antigen presentation (MHC I and MHC II), co-
stimulation (CD40, CD80), cell adhesion (CD54, ICAM-1) and apoptosis (Fas, FasL) 
on the surface of the epithelial cells (Mavragani and Moutsopoulos 2014). 
Lymphocyte infiltrates in the diseased glands comprise autoreactive T-cells, which 
escape cell death due to a defective peripheral Fas/FasL-dependent mechanism of 
tolerance (Hayashi et al. 2004). This may cause T-cells polarization to IFNγ-
producing Th1 cells, being contributors to epithelial lesion in SS (Segerberg-
Konttinen et al. 1987; Konttinen et al. 1999; Mitsias et al. 2002). Besides this, other 
immunocompetent cells, identified as Th17, subset of NK-cells, also CD8+ cells are 
found in the lymphocyte infiltrates. Such aggressive inflammatory milieu favors 
intensive apoptosis of the epithelial cells, turning them into a source of autoantigens. 
Epithelium-derived apoptotic bodies, microparticles and exosomes contain 
pathologically processed cryptic epitopes and immunogenic determinants. They are 
consumed by immature plasmacytoid dendritic cells and presented subsequently to T-
cells. In turn, activated T-cells initiate B-cell polarization into autoantibody-producing 
plasma cells, therefore inducing/enhancing the vicious cycle of SS pathogenesis. 
Indeed, one of the diagnostic criteria for SS is the presence of serum autoantibodies 
directed against SS-A/B hY RNA ribonucleoproteins.  
Taken together our results on altered H-receptor profile along with altered OCT3 
transporter in the salivary epithelium in SS patients and recently reported anti-
apoptotic features of submicromolar histamine in rodents (Medina et al. 2011; 
Carabajal et al. 2012; Prestifilippo et al. 2012), it was hypothesized that activation of 
H4R may provide anti-apoptotic effect in salivary glands as well. Based on our results 
herein we report that activation of H4R with nanomolar concentrations of selective 
receptor agonist HST-10 results in inhibition of TNFα/IMD0354-induced apoptosis in 
NS-SV-AC cells. In the salivary glands H4R is activated by nanomolar locally 
produced and continuously released histamine from the ductal epithelial cells. 
Considering Fas-apoptosis as a key event in disease pathogenesis our findings suggest 
a protective role of H4R against T-cell-mediated apoptosis in the salivary glands. 
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Thus, dramatically diminished expression of OCT3 transporter together with down-
regulated expression of H4R contributes to the development of the disease. 
Results of Western blot and qRT-PCR experiments provided us with the data 
revealing underlying mechanisms of H4R-driven protection against apoptosis. H4R 
stimulation inhibited phosphorylation of JNK, a MAPK, which is considered to be a 
pro-apoptotic process. At the same time phosphorylation of anti-apoptotic ERK 
remained unchanged. These changes in the MAPK pathway should protect cells form 
apoptosis (Boucher et al. 2000). Activation of H4R resulted in up-regulation of anti-
apoptotic Bcl-XL on protein and mRNA levels, while expression of pro-apoptotic 
BAX protein was not changed upon H4R stimulation in the presence of apoptosis 
inducers. This indicates that H4R signaling shifts the balance of Bcl-2 family 
members in favor of cell survival. 
Our results on anti-apoptotic low nanomolar histamine function are in agreement 
with those of the research group in Buenos Aires, Argentina. To our knowledge it is 
the only group, who is actively studying protective functions of H4R. The mainstream 
of their research comprises histamine-mediated protection against radiation-induced 
cell damage and apoptosis in vivo (Martinel Lamas et al. 2013) and anti-proliferative 
activity of H4R in cancer in vitro (Medina et al. 2011; Martinel Lamas et al. 2015). 
Besides anti-apoptotic activity of H4R in vitro, we have also demonstrated indirect 
evidence that H4R regulates production of harmful IL-8 and VEGF, which are 
suggested to play a role in SS. High micromolar concentrations of another specific 
H4R agonist ST-1006 were applied to epithelial HSG cells. This resulted in  increased 
production of both IL-8 and VEGF by the cells. This might be explained by 
desensitization/down-regulation of H4R in response to an overstimulation with high 
concentration of receptor’s ligand, as released form  mast cell-derived histamine in 
vivo or selective agonist in vitro. In salivary glands this response may also be 
aggravated by a possibly reduced withdraw of the excessive ductal epithelium   
histamine due to lack of major histamine transporters such as OCT3. On the other 
hand, pro-inflammatory cytokines like IL-8 and VEGF and others may also down-
regulate H4R expression. Both possibilities of high dose histamine-dependent and 
inflammatory milieu-mediated down-regulation of H4R have been demonstrated by 
other members of our group (Salem et al. 2015). In turn, diminished activity of H4R 
predisposes salivary epithelium to the development and progression of SS by creating 
a locally enhanced apoptotic precondition.  
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7.5. Regulation of H4R expression 
 
One of Sjögren’s syndrome’s marked 
features is the female dominance with ratio 9:1, 
which suggests syndrome is a sex steroid-
associated disease. Recently it was reported 
that SS patients are androgen depleted both 
systemically due to adrenopause and locally in 
salivary glands due to a defective intracrine sex 
steroid synthesizing enzymatic machinery 
(Porola et al. 2008; Spaan et al. 2009). 
Furthermore, H4R expression in salivary 
epithelium may be reduced in patients with SS 
as suggested by the results of the present study. 
Taking together these two aspects of SS we 
have hypothesized that the expression of glandular H4R is an androgen-dependent 
phenomenon. Our earlier unpublished results obtained using qRT-PCR with TaqMan 
technology showed that mRNA levels of moH4R tend to be lower in salivary glands 
from orchidectomized HDC+/HDC+ genotype mice as compared to intact control 
animals (Figure 15). This preliminary observation somewhat supports the hypothesis 
that diminished expression of H4R in SS may be in part due to low systemic and local 
levels of androgens.   
Thus, based on results of this project and others it can be concluded that there are 
only few known mechanisms, which could lead to reduced expression of H4R in 
salivary glands. At present, however, mechanisms involving a harmful local 
inflammatory milieu, including high levels of mast cell-derived histamine and a 
local/systemic androgen depletion are partly supported by results of this project.  
  
Figure 15. Relative expression of H4R mRNA 
in murine salivary glands, normalized to β-
actin. Number of samples in each group = 4.
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8. SUMMARY AND CONCLUSIONS 
 
In 1910 Sir Henry Hallett Dale discovered histamine as a contaminant of ergot 
generated by bacterial action. The name “histamine” originates from the Greek word 
“histos” (ἱστός) meaning tissue. Significance of this important biologically produced 
amine in medicine and biology was discovered several years later and the first 
clinically used antihistamine phendenzamine was synthesized and therapeutically 
applied in 1942 by Bernard N. Halpern. 
The autoimmune alteration of major exocrine glands was discovered in 1933 by 
Swedish ophthalmologist Henrik Sjögren, who described sicca syndrome in his 
doctoral thesis at Karolinska Institutet entitled “On knowledge of 
keratoconjunctivitis”. Later on, the syndrome was named after the discoverer. 
Sjögren's syndrome still remains a disease with elusive etiology and unclear 
complicated pathogenesis, since many theories have been proposed to explain the 
causes of the disease. 
Today clinically used H1R- and H2R-antagonists are ineffective in treatment of 
autoimmune diseases and have vanished from this therapy field. It has also been 
reported, that many cells throughout the human body produce histamine in small 
amounts. This finding received little attention until 1994 when the new high affinity 
H4R was pharmacologically discovered in immunocompetent cells and a new era of 
histamine-mediated immunomodulatory effects had begun. It was hypothesized that 
H4R is also implicated in Sjögren’s syndrome pathogenesis. This thesis study shows 
the important role of H4R in the affected salivary glands and why diminished 
expression of the receptor along with locally altered histamine transport is harmful 
and favors development and progression of Sjögren’s syndrome. Our main 
conclusions of the study are: 
 
1. Acinar and ductal epithelial cells of healthy salivary glands express H4R on mRNA 
and protein levels. Based on immunohistochemical staining, H4R expression seems 
to be lower in salivary glands of SS patients.  
 
2. Salivary ductal epithelium is fully equipped with a histamine synthesizing, 
transporting and degradation machinery. This defines salivary epithelial cells as 
HDC-containing non-professional histamine producing cells, allowing H4R 
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activation in auto- and paracrine manners. This finding also suggests a mast cell-
derived histamine removal function of the epithelial cells, which consists of 
histamine up-take, subsequent intracellular degradation by HNMT and outflow 
into saliva. Our studies propose OCT3, a passive membrane cation exchanger, as a 
major histamine transporter in glandular epithelium. Expression of OCT3-based 
histamine transport system is drastically diminished in SS on both mRNA and 
protein levels. This may result in accumulation of mast cell-derived harmful high 
histamine amounts in extracellular space of the salivary glands in SS and exert 
H1R-mediated pro-inflammatory effects. Extracellular histamine degradation in 
salivary glands is rather impossible due to very low, if any, expression of DAO. 
Thus, this study has also partly revealed the role of mast cells in SS that has since 
long been suspected. 
 
3. Based on these thesis results it can be concluded that H4R plays role in homeostatic 
maintenance of the glandular epithelium. It was demonstrated, that overstimulation 
of H4R results in enhanced production of pro-inflammatory IL-8 and VEGF in 
vitro. We also show that H4R selective activation results in inhibition of Fas-
apoptosis, which is considered as a key event in SS pathogenesis. Underlying 
mechanisms of H4R-mediated anti-apoptotic activity comprise inhibition of JNK 
MAPK pathway and shift in the balance within Bcl-2 family proteins in favor of 
cell survival by up-regulating Bcl-XL anti-apoptotic protein. 
 
4. This thesis project also aimed at preliminarily searching the mechanisms which 
might down-regulate H4R expression in salivary glands. It seems, that locally 
increased pro-inflammatory cytokine production inside the lymphocytic foci and 
accumulation of mast-cell derived histamine and local/systemic androgen 
deficiency may be proposed as suppressive candidates for H4R expression. These 
preliminary findings were obtained from mouse salivary glands and supported by 
scant in vitro studies by other investigators. Further investigation is required on 
this matter.  
 
5. All presented data are novel reported findings and do not reproduce earlier 
performed and published experiments of others. New roles for nanomolar 
histamine have been proposed. The failure of those H4R-driven mechanisms can 
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contribute to SS pathogenesis. For the future we believe that newly synthesized 
low molecular weight H4R agonists along or together with mast cell stabilizers 
might provide alternatives to expensive widely used biologicals for the treatment 
of autoimmune diseases, including Sjögren’s syndrome. 
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9. SUMMARY AND CONCLUSIONS in RUSSIAN 
 
Гистамин был открыт в 1910 году сэром Генри Галлеттом Дейлом как 
побочный продукт бактериальной ферментации спорыньи. Термин «гистамин» 
происходит от греческого слова гистос (ἱστός), что значит ткань. Годами позже 
была открыта его биологическая и медицинская значимость, а первый 
антигистаминовый препарат фендензамин был синтезирован и применен в 
лечебной практике Бернардом Н. Халперном в 1942 году. 
Аутоиммунное поражение основных экзокринных желез было открыто в 
1933 году шведским офтальмологом Хенриком Шегреном. Он описал синдром 
сухости в своей докторской диссертации «К вопросу о кератоконъюнктивите», 
которую защитил в Каролинском университете. Позднее синдром был назван в 
честь своего первооткрывателя. Много теорий было предложено для  
объяснения причин синдрома Шегрена (СШ), но и по сей день он остается 
заболеванием с ускользающей от исследователей этиологией и с неясным 
патогенезом. 
Используемые сегодня H1- и H2-антигистаминовые препараты неэффективны 
в лечении аутоиммунных заболеваний, и поэтому не используются в данном 
терапевтическом назначении. Исследования показывают, что гистамин 
синтезируется в малых количествах по всему организму человека. Это открытие 
не получало заслуженного внимания до тех пор, пока в 1994 году в 
иммунокомпетентных клетках не был открыт новый высокоаффинный рецептор 
Н4R, что положило начало новой иммуномодуляторной гистаминовой эре. Было 
предположено, что Н4R вовлечен в патогенез синдрома Шегрена. Данная 
диссертационная работа показывает важную роль этого рецептора в 
пораженных слюнных железах и объясняет, чем сниженная экспрессия 
рецептора, наряду с локально поврежденным транспортом гистамина, является 
вредоносным и способствует развитию и прогрессу заболевания. Основные 
выводы работы: 
 
1. Ацинарные и дуктальные клетки здорового эпителия слюнных желез 
экспрессируют Н4R как на мРНК, так и на белковом уровнях. Основываясь на 
результатах иммуногистохимии, экспрессия Н4R представляется сниженной в 
слюнных железах больных СШ.  
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2. Канальцевый эпителий слюнных желез полностью оснащен механизмами, 
необходимыми для синтеза, транспорта и деградации гистамина ферментами 
и транспортерами, в частности гистидиндекарбоксилазой (HDC), гистамин N-
метилтрансферазой (HNMT) и транспортером органических катионов-3 
(OCT3). Это определяет HDC-содержащие клетки эпителия как 
непрофессиональные гистамин-продуцирующие клетки и дает возможность 
для аутокринной и паракринной активации H4R. На основании данного 
положения также можно предположить, что слюнные эпителиальные клетки 
выполняют функцию утилизации сравнительно больших объемов гистамина, 
высвобожденного в результате дегрануляции тучных клеток, путем его 
захвата и деградации ферментом HNMT с дальнейшим выведением со 
слюной. Наши исследования предлагают ведущую роль OCT3 в транспорте 
гистамина в эпителии слюнных желез. Экспрессия этого пассивного 
мембранного обменника катионов в слюнных железах больных СШ 
значительно снижена на уровнях белка и мРНК. В свою очередь, это может 
служить причиной накопления высвобожденного из тучных клеток 
гистамина высоких концентраций в ткани слюнных желез больных СШ с 
последующим усилением местных H1R-опосредованных воспалительных 
реакций. Согласно нашим данным, внеклеточная деградация гистамина в 
слюнных железах невозможна в результате отсутствия фермента 
диаминооксидазы (DAO). Таким образом, данное исследование также 
частично описывает вовлеченность тучных клеток в СШ, чья роль в 
патогенезе данного заболевания подозревалась уже довольно давно. 
 
3. Основываясь на результатах данной работы, можно заключить, что H4R 
играет роль в поддержании гомеостаза эпителия слюнных желез. Было 
продемонстрированно, что чрезмерная стимуляция H4R приводит к 
увеличению продукции провоспалительных цитокинов IL-8 and VEGF in 
vitro. Также было показано, что селективная активация H4R ингибирует Fas-
опосредованный апоптоз, ключевое событие в патогенезе CШ. 
Молекулярные механизмы H4R-опосредованного антиапоптотического 
эффекта включают в себя ингибирование JNK MAPK сигнального пути и 
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сдвиг баланса внутри белковой группы Bcl-2 с преимущественным 
увеличением синтеза антиапоптотического белка Bcl-XL. 
 
4. Данная диссертационная работа также ставила задачи по поиску причин 
снижения экспрессии H4R в слюнных железах у больных СШ. С 
определенной долей вероятности можно предположить, что локально 
увеличенная продукция провоспалительных цитокинов в фокусных 
скоплениях лимфоцитов и аккумуляция высвобожденного из тучных клеток 
гистамина а также локальный и системный дефицит андрогенов, являются 
основными супрессивными кандидатами для подавления синтеза и 
экспрессии H4R. Легшие в основу данного вывода наблюдения были 
получены в экспериментах с мышиными слюнными железами и 
подкрепляются небольшим количеством сторонних исследований in vitro. 
Более подробное объяснение данных наблюдений требуют дальнейших 
исследований. 
 
5. Все представленные данные являются новыми и не повторяют ранее 
проведенных и опубликованных результатов экспериментов. Предложены 
новые роли гистамина наномолярных концентраций. Нарушения описанных 
H4R-опосредованных механизмов могут быть вовлечены в патогенез СШ. 
Мы полагаем, что новые синтетические низкомолекулярные агонисты H4R 
совместно со стабилизаторами тучных клеток в будущем могут служить 
альтернативой повсеместно используемым дорогостоящим биологическим 
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